AU2001266232B2 - Colchinol derivatives as angiogenesis inhibitors - Google Patents

Colchinol derivatives as angiogenesis inhibitors Download PDF

Info

Publication number
AU2001266232B2
AU2001266232B2 AU2001266232A AU2001266232A AU2001266232B2 AU 2001266232 B2 AU2001266232 B2 AU 2001266232B2 AU 2001266232 A AU2001266232 A AU 2001266232A AU 2001266232 A AU2001266232 A AU 2001266232A AU 2001266232 B2 AU2001266232 B2 AU 2001266232B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
formula
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001266232A
Other versions
AU2001266232A1 (en
Inventor
Jean Claude Arnould
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogene Pharmaceuticals Ltd
Original Assignee
Angiogene Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharmaceuticals Ltd filed Critical Angiogene Pharmaceuticals Ltd
Publication of AU2001266232A1 publication Critical patent/AU2001266232A1/en
Application granted granted Critical
Publication of AU2001266232B2 publication Critical patent/AU2001266232B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

WO 02/08213 PCT/GB01/02964 COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS The present invention relates to vascular damaging agents, to the use of compounds of the invention in the manufacture of medicaments for use in the production of antiangiogenic effects in warm-blooded animals such as humans, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds as active ingredient, to methods for the treatment of disease states associated with angiogenesis and to the use of such compounds as medicaments.
Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Formation of new vasculature by angiogenesis is a key pathological feature of several diseases Folkman, New England Journal of Medicine 333, 1757-1763 (1995)). For example, for a solid tumour to grow it must develop its own blood supply upon which it depends critically for the provision of oxygen and nutrients; if this blood supply is mechanically shut off the tumour undergoes necrotic death. Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of rheumatoid arthritis patients and of atherosclerotic plaques. Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy.
Reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect. The present invention is based on the discovery of tricyclic compounds that surprisingly specifically damage newly formed vasculature without affecting the normal, established vascular endothelium of the host species, a property of value in the treatment of disease states associated with angiogenesis such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation.
Compounds of the present invention are colchinol derivatives. Colchinol derivatives for example N-acetyl-colchinol are known. Anti-tumour effects have been noted on animal WO 02/08213 PCT/GB01/02964 -2models (see for example Jnl. Natl. Cancer Inst. 1952, 13, 379-392). However, the effect studied was that of gross damage (haemorrhage, softening and necrosis) and there is no suggestion of treatment of inappropriate angiogenesis by destruction of neovasculature.
It is believed, though this is not limiting on the invention, that the use of compounds of the invention damages newly-formed vasculature, for example the vasculature of tumours, thus effectively reversing the process of angiogenesis as compared to known anti-angiogenic agents which tend to be less effective once the vasculature has formed.
According to one aspect of the present invention there is provided a compound of the formula 3 N(R7)-A-[CH(Ra)1a-B-[CH(Rb)]b-D I2 4 R1
R
R
6 R (1) wherein:
R
1 R2 and R 3 are each independently hydroxy, phosphoryloxy (-OP0 3
H
2
C
14 alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R R 2 and R 3 are Ci4alkoxy; A is CO-, -CON(R 8
-SO
2 or -SO 2
N(R
8 (wherein R 8 is hydrogen, Ci- 4 alkyl, Cl-3alkoxyCi-3alkyl, aminoC 1 3 alkyl or hydroxyCl-3alkyl); a is an integer from 1 to 4 inclusive;
R
a and Rb are independently selected from hydrogen, hydroxy and amino; B is -N(R 9
-CON(R
9
-N(R
9
N(R
9
-N(R
9
-N(R
9 )S0 2
-SO
2
N(R
9 or a direct single bond (wherein R 9 and R' 1 are independently selected from hydrogen, C 1 .4alkyl, Ci-3alkoxyCl-3alkyl, aminoCi_3alkyl and hydroxyC1.3alkyl); b is 0 or an integer from 1 to 4 inclusive, (provided that when b is 0, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino, WO 02/08213 PCT/GB01/02964 -3- N-(Cl- 4 alkyl)amino, N,N-di(Ci- 3 alkyl)amino or of the formula -Y'-(CH 2 )Rl' or
-NHCH(R
12 )COOH; [wherein Y' is a direct single bond, -N(R" 3
-N(R'
3 or -C(O)N(R' 3 (wherein R 13 is hydrogen, C 1 4 alkyl, Cl-3alkoxyC 2 3 alkyl, aminoC 2 3 alkyl or hydroxyC 2 3 alkyl); c is 0 or an integer from 1 to 4 inclusive; R" is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O, S and N, or a 5-6-membered unsaturated or partially unsaturated heteroaryl group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently form 0, S and N, which heterocyclic group or heteroaryl group may bear 1 or 2 substituents selected from: oxo, hydroxy, halogeno, C 1 4 alkyl, C2- 4 alkanoyl, carbamoyl, N-(CI- 4 alkyl)carbamoyl, NN-di-(C 4 alkyl)carbamoyl, hydroxyC 1 4 alkyl, C 1 4 alkoxy, cyanoC 1 3 alkyl, carbamoylCI 3 alkyl, carboxyCI- 4 alkyl, aminoC 1 4 alkyl, N-C- 4 alkylaminoCI1-4alkyl, di-NN-(CI- 4 alkyl)aminoCl- 4 alkyl, C 1 4 alkoxyCI- 4 alkyl, C 4 alkylsulphonylCi- 4 alkyl and R' 4 (wherein R' 4 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing I or 2 ring heteroatoms, selected independently from O, S and N, which heterocyclic group is optionally substituted by 1 or 2 substituents selected from: oxo, hydroxy, halogeno, C 1 4 alkyl, hydroxyC 1 4 alkyl, C 1 4 alkoxy, Ci- 4 alkoxyCi- 4 alkyl and C 1 4 alkylsulphonylC 1 4 alkyl); R12 is an amino acid side chain;
R
5 is Cl 4 alkoxy;
R
4 and R 6 are each independently selected from: hydrogen, fluoro, nitro, amino, N-CI- 4 alkylamino, N,N-di-(C1- 4 alkyl)amino, hydroxy,
CI-
4 alkoxy and CI-4alkyl;
R
7 is hydrogen, CI- 4 alkyl, CI.3alkoxyCi-3alkyl, amrninoCi.
3 alkyl orhydroxyC 1 3 alkyl; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
In another aspect, the invention relates to a compound of the formula as hereinabove defined or to a pharmaceutically-acceptable salt thereof.
In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only and references to individual branched-chain WO 02/08213 PCT/GB01/02964 -4alkyl groups such as "isopropyl" are specific for the branched-chain version only. An analogous convention applies to other generic terms.
R
1 2 is an amino acid side chain. This includes side chains from natural and nonnatural amino acids and includes the possibility of R 1 2 joining to the NH group so as to form a ring as in the amino acid proline. It includes a-amino acids p-amino acids and y-amino acids.
In addition, the amino acids may be L-isomers or D-isomers, but preferably L-isomers.
Preferred amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparaginine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, p-alanine and ornithine.
More preferred amino acids include glutamic acid, serine, threonine, arginine, glycine, alanine, p-alanine and lysine. Especially preferred amino acids include glutamic acid, serine, threonine, arginine, alanine and p-alanine. Specific values for R12 include hydrogen, C 1 i 4 alkyl, Cl-4alkylthioCi4alkyl, hydroxyCl-4alkyl, thioCi-4alkyl, phenylCl-4alkyl (optionally substituted by hydroxy), guanidinoC_4alkyl, carboxyCI 4 alkyl, carbamoylCl4alkyl, aminoCi 4 alkyl and imidazolyl C -4alkyl and R 12 forming a pyrrolidinyl ring with the NH group.
Preferred values for R 12 include hydrogen, C-4alkyl, Cl 4 alkylthioCl 4 alkyl, hydroxyC 1 -4alkyl, thioCl-4alkyl, guanidinoC-4alkyl, carboxyC- 4 alkyl, carbamoylCl-4alkyl and aminoC-4alkyl.
It is to be understood that, insofar as certain of the compounds of Formula defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses vascular damaging activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.
Suitable values for the generic radicals referred to above include those set out below.
Within the present invention it is to be understood that a compound of the formula or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which has vascular damaging WO 02/08213 PCT/GB01/02964 activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
It is also to be understood that certain compounds of the formula and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which have vascular damaging activity.
The present invention relates to the compounds of formula as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochloridcs, hydrobromidcs, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates. In addition where the compounds of formula are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
Various forms ofprodrugs are known in the art. For examples of such prodrug derivatives, see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991); WO 02/08213 WO 0208213PCT/GB01/02964 -6.
c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard, et at., Journal of Pharmaceutical Sciences, 7, 285 (1988); and e) N. Kakeya, et al., Chem. Pharm. BulL, 32, 692 (1984).
Examples of such pro-drugs may be used to form in-vivo-cleavable esters of a compound of the Formula An in-vivo-cleavable ester of a compound of the Formula (D) containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceuticallyacceptable esters for carboxy include CI- 6 alkoxymethyl esters, for example methoxymethyl; C 1 6 alkanoyloxymethyl esters, for example pivaloyloxymethyl; phthalidyl esters; C 3 .gcycloalkoxycarbonyloxy C 1 6 alkyl esters, for example 1 -cyclohexylcarbonyloxyethyl; I ,3-dioxolan-2-ylmethyl esters, for example 1 ,3-dioxolan-2-ylmethyl; and C 1 6 alkoxycarbonyloxyethyl esters, for example I -methoxyearbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention.
Suitable values for R 2 substituents on D or R 1 4 include: for halogeno for C 1 4 alkyl: for N-CI- 4 alkylamino: for N,N-di-[C 1 4 alkyl] amino: for C 2 4 alkanoyl: for CI- 4 alkoxy: for cyanoCI 1 4 alkyl: for N-Ci- 4 alkylcarbamoyl: for NN-di-[(Ci-4))alkyl]carbamoyl: for C 1 4 alkylsulphonylalkyl: for hydroxyCI- 4 alkyl: R',R 8
R
9 R'O or R3or for various fluoro, chioro, bromo and iodo; methyl, ethyl, propyl, isopropyl and tert-butyl; methylamino, ethylamino, propylamino, isopropylamino and butylamino; dimethylamino, diethylamino, N-ethyl- N-methylamino and diisopropylamino; acetyl and propionyl; methoxy and ethoxy; cyanomethyl and 2-cyanoethyl; N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl; NN-dimethylcarbamoyl, N-ethyl- N-methylcarbamoyl and NN-diethylcarbamoyl; methylsulphonylmethyl and ethylsulphonylmethyl; hydroxymethyl, 2-hydroxyethyl, I -hydroxyethyl and 3-hydroxypropyl as appropriate; WO 02/08213 WO 0208213PCT/GB01/02964 for CI- 4 alkoxyC 1 4 alkyl: for aminoC 1 4 alkyl for N-C 1 4 alkylaminoC, 1 4 alkyl: methoxymethyl, ethoxymethyl, 1 -methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl and 3-methoxypropyl as appropriate; amninomethyl, 2-aminoethyl, 1-aminoethyl and 3-amninopropyl. as appropriate; methylaminomethyl, ethylaminomethyl, 1-methyl aminoethyl, 2-methyl aminoethyl, 2-ethylaminoethyl and 3-methylamninopropyl as appropriate; dimethylaminomethyl, diethylaminomethyl, 1 -dimethylaminoethyl, 2-dimethylamirioethyl and 3-dimethylaminopropyl as appropriate: carboxymethyl, I -carboxyethyl, 2-carboxyethyl, 3-carboxypropyl and 4-carboxybutyl; carbamoylmethyl, 1 -carbamoyl ethyl, 2-carbamoylethyl and 3-carbamoylpropyl; methoxymethyl, ethoxyethyl, methoxyethyl, and methoxypropyl.
for N,N-di-[C 1 4 alkyl]aminoC 1 4 alkyl: for carboxyCl- 4 alkyl: for carbamoylC 14 alky1: for CI- 4 alkoxyC I -alkyl Carbamoyl refers to CONH 2 Piperazino refers to piperazin- 1-yl.
Examples of 5- or 6-membered saturated heterocyclic groups include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl.
Examples of 5- or 6-membered unsaturated or partially unsaturated heteroaryl groups include: imidazolyl, imidazolinyl pyridyl pyrrolyl, furanyl, triazolyl, pyrazinyl, pyrazolinyl, pyrimidinyl, pyridazinyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl and thienyl.
Preferably at least 2 of R 1 R 2 and R 3 are methoxy.
Preferably R1 R 2 and R(3 are all C 1 4 alkoxy.
Most preferably R 1 R 2 and R 3 are all methoxy.
WO 02/08213 PCT/GB01/02964 -8- Preferably R 8 is hydrogen, methyl, ethyl, 2-methoxyethyl, 2-aminoethyl or 2-hydroxyethyl.
More preferably R 8 is hydrogen, 2-aminoethyl or 2-hydroxyethyl and most preferably R is hydrogen.
Preferably A is or -CON(R 8 Most preferably A is Preferably a is 1, 2 or 3 and most preferably a is 2 or 3.
Preferably Ra, and Rb are hydrogen.
Preferably B is -N(R 9
-CON(R
9
-N(R
9
-N(R
9
N(R
9 )CON(Ri')- or a single direct bond.
More preferably B is -N(R 9 )CO- or a single direct bond.
Yet more preferably B is -CO- or a single direct bond.
Most preferably B is In another aspect B is a single direct bond.
Preferably R 9 and R' 0 are independently selected from hydrogen, methyl, ethyl, 2-methoxyethyl, 2-aminoethyl and 2-hydroxyethyl.
More preferably R 9 and R' 1 are independently selected from hydrogen, 2-aminoethyl and 2-hydroxyethyl.
Most preferably R 9 and R 10 are hydrogen.
Preferably b is 0, 1 or 2, more preferably b is 0 or 1 and most preferably b is 0.
Preferably R 11 is a 5 or 6 membered saturated heterocyclic ring containing 1 or 2 ring heteroatoms selected from N and 0.
More preferably R 1 is a 6 membered saturated heterocyclic ring containing 1 or 2 ring heteroatoms selected from N and 0.
Further preferably R 11 contains at least I ring nitrogen atom.
Further preferably R 1 is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 of the substituents mentioned above for R'.
Further preferably R 11 is linked via a ring nitrogen atom.
Most preferably R" is piperazino or morpholino, each ring being optionally substituted by 1 or 2 of the substituents mentioned hereinabove for R".
The saturated heterocyclic ring may be substituted on ring carbon or ring nitrogen atoms, providing this does not result in quatemisation.
WO 02/08213 PCT/GB01/02964 -9- Preferred substituents for the saturated heterocyclic ring in R" include C 1 4 alkyl,
C
2 4 alkanoyl, carbamoyl, cyanoC 1 3 alkyl, hydroxyC.
3 alkyl, carboxyC l 3 alkyl and aminoC 1 3 alkyl.
More preferred substituents for the saturated heterocyclic ring in R" include CI-3alkyl, C2-3alkanoyl, carbamoyl and hydroxyC 2 3 alkyl.
Yet more preferred substituents for the saturated heterocyclic ring in include methyl, acetyl, carbamoyl and 2-hydroxyethyl.
The most preferred substituents for the saturated heterocyclic ring include methyl, acetyl and carbamoyl.
Preferably the saturated heterocyclic ring in R" is unsubstituted or substituted by 1 substituent.
When the saturated heterocyclic ring in R" is morpholino, preferably it is unsubstituted. When the saturated heterocyclic ring in R" is piperazino, preferably it is unsubstituted or substituted by 1 substituent on a ring nitrogen atom.
Preferably Y' is -CONH or -NHCO Preferably c is 0, 1 or 2.
More preferably c is 0.
Preferred values for R" include morpholino, 4-methylpiperazin-1-yl and 4-acetylpiperazin- l-yl.
Preferably R' 4 is morpholino or piperazin-1-yl, each optionally substituted by 1 or 2 substituents selected from C 1 3 alkyl, hydroxyC 2 3 alkyl, CI-3alkoxy and C 1 3 alkoxy Cl-3alkyl.
More preferably R14 is morpholino, or piperazin-l-yl unsubstituted or substituted by methyl.
Preferably D is carboxy, phosphoryloxy, hydroxy, amino, N-CI- 4 alkylamino, N,N-di(Ct-4 alkyl)amino or of the formula -Y 1
(CH
2 wherein Y' c and R" are as hereinabove defined.
More preferably D is carboxy phosphoryloxy, hydroxy, amino or of the formula
-Y'-(CH
2 wherein Y' ,c and R' 1 are as hereinabove defined.
More preferably D is phosphoryloxy, amino or of the formula -Y'-(CH 2 1 wherein c and R 1 are as hereinabove defined.
WO 02/08213 PCT/GB01/02964 Yet more preferably D is phosphoyloxy, amino or of the formula -Y'-(CH2)cR" wherein Y' and c are as hereinabove defined and R" is morpholino, imidazolyl, or piperazinyl, which heterocyclic group may bear one or more substituents as defined above.
Yet more preferably D is phosphoyloxy, amino or of the formula -Y 1
-(CH
2 wherein Y' and c are as hereinabove defined and R 1 is morpholino, imidazolyl, 4-methylpiperazin-l-yl or 4-acetylpiperazin-l-yl.
Yet even more preferably D is phosphoyloxy, amino or of the formula -Y 1
-(CH
2 )cR 1 wherein Y' is a direct single bond and c is 0 and R' is morpholino, imidazol-l-yl, 4-methylpiperazin- 1-yl or 4-acetylpiperazin- 1-yl.
Preferably R 5 is methoxy.
Preferably R 4 and R 6 are independently selected from hydrogen, hydroxy, C -3 alkoxy, and Cl-3alkyl.
More preferably at least one of R 4 and R 6 is hydrogen.
Most preferably R 4 and R 6 are both hydrogen.
Preferably R 7 is hydrogen or methyl. Most preferably R 7 is hydrogen.
A preferred class of compound is of the formula wherein: R R 2 and R 3 are all C 14 alkoxy;
R
4 and R 6 are independently selected from hydrogen, hydroxy, C|-3 alkoxy, and Ci-3alkyl;
R
5 is methoxy; A is or -CONH-; ais 1, 2 or 3; B is -NHCO-, -CONH, -NHC(O)O-, NHCONH- or a single direct bond; b is0, 1 or 2; D is carboxy, sulpho, phosphoryloxy, hydroxy, amino, N-CI- 4 alkylamino, N,N-di(Cl-4 alkyl)amino or of the formula -Y'(CH 2 )cR" (wherein Y1 is -NHC(O)- or c is 1 or 2; R 1 is a 5-6-membered saturated heterocyclic group (linked via nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group may bear 1 or 2 substituents selected from: WO 02/08213 PCT/GB01/02964 -11- CI-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoCi- 3 alkyl, hydroxyCl-3alkyl, carboxyCi.3alkyl and aminoC-1 3 alkyl);
R
7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
Another preferred class of compound is of the formula wherein:
R
I
R
2 and R 3 are all methoxy;
R
4 and R 6 are independently selected from hydrogen, hydroxy, methoxy and methyl;
R
5 is methoxy; A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is carboxy, phosphoryloxy, hydroxy, amino, N-CI- 4 alkylamino, N,N-di(C 1 4 alkyl)amino or of the formula -Y 1
(CH
2 )cR" (wherein Y' is -NHC(O)- or c is 1 or 2; R 11 is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from:
C
1 4 alkyl, C 2 4 alkanoyl, carbamoyl, cyanoCl- 3 alkyl, hydroxyCl-3alkyl, carboxyC 1 3 alkyl and aminoCi_ 3 alkyl);
R
7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
Another preferred class of compounds is that of the formula (II): MeO NH-A-(CH2)a-B-(CH2)b-D MeO MeO OMe
(II)
wherein a, b, A, B and D are as hereinabove defined; WO 02/08213 PCT/GB01/02964 -12or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Another preferred class of compounds is that of the formula (II) wherein: A is or -CONH-; ais 2 or3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is carboxy, phosphoryloxy, hydroxy, amino, N-CI- 4 alkylamino, N,N-di(Ci- 4 alkyl)amino or of the formula -Y'(CH 2 )R"1 (wherein Y' is -NHC(O)- or c is 1 or 2; R" is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from: Ci- 4 alkyl, C24alkanoyl, carbamoyl, cyanoCi- 3 alkyl, hydroxyCi- 3 alkyl, carboxyC 1 -3alkyl and aminoCl-3alkyl); or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Another preferred class of compounds is that of the formula (II) wherein: A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; bis0or 1; D is phosphoryloxy, carboxy, amino or imidazolyl; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Another preferred class of compounds is that of the formula (II) wherein: A is or -CONH-; a is 2 or 3; B is -NHCO- or a single direct bond; b is 0 or 1; D is phosphoryloxy amino or imidazolyl; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
WO 02/08213 WO 0208213PCT/GB01/02964 13 A further preferred class of compounds of the invention is that of a compound of formula (111):: 3
R
6 wherein:
R
1 R 2 and R 3 are each independently hydroxy, phosphoryloxy (-0P0 3
H
2 Ci- 4 alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of RI, R 2 and R 3 arc
C
1 4 alkoxy; A is CO-, -CON(R 8
-SO
2 or SO 2
N(R
8 (wherein R 8 is hydrogen, CI- 4 alkyl, C I 3 alkoXYC 2 3 alkyl, aminoC 2 3 alkyl or hydroxyC 23 alkyl); a is an integer from 1 to 4 inclusive; W~and R b are independently selected from hydrogen, hydroxy and amino; B is -N(R 9
-CON(R
9
-N(R
9
N(R
9
-N(R
9
)CON(R'
0
-N(R
9 )S0 2
-SO
2
N(R
9 or a direct single bond (wherein R 9 and R 10 are independently selected from hydrogen, C 14 alkyl, C 1 3 a~koxyC 2 3 alkyl, aminoC 2 3 alkyl and hydroXYC 23 alkyl); b is 0 or an integer from 1 to 4 inclusive; D is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from 0 and N, which heterocyclic group may bear I or 2 substituents selected from: oxo, hydroxy, halogeno, C 14 alkyl, C 2 4 alkanoyl, carbamoyl, N-(CI- 4 alkyl)carbamoyl, NN-di-(C 1 4 alkyl)carbamoyl, hydroxyCl- 4 alkyl, C 1 4 alkoxy, cyanoC 1 3 alkyl, carbamoylC 1 3 alkyl, carboxyCI 4 alkyl, aminoC 1 4 alkyl, N-C 1 4 alkylaminoC, 4 alkyl, di- N N-(CI- 4 alkyl)aminoC 1 4 alkyl, C 1 4 alkoxyCI- 4 alkyl, CI- 4 alkylsulphonylCl 1 4 alkyl and R 14(wherein R'1 4 is a 5-6-membered saturated heterocyclic group (linked via carbon or WO 02/08213 PCT/GB01/02964 -14nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group is optionally substituted by I or 2 substituents selected from: oxo, hydroxy, halogeno, Cl-4alkyl, hydroxyCi-4alkyl, CI-4alkoxy,
C
1 4 alkoxyCi.
4 alkyl and C 14 alkylsulphonylCi- 4 alkyl);
R
5 is Cl-4alkoxy;
R
4 and R 6 are each independently selected from: hydrogen, halogeno, nitro, amino, N-Cl.
4 alkylamino, N,N-di-(C-1 4 alkyl)amino, hydroxy, Ci.
4 alkoxy and C-4alkyl;
R
7 is hydrogen, Ci-4alkyl, Ci-3alkoxyCl-3alkyl, aminoCl-3alkyl or hydroxyCl-3alkyl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
Another further preferred class of compound is of the formula wherein: R R 2 and R 3 are all C 4 alkoxy;
R
4 and R 6 are independently selected from hydrogen, hydroxy, CI-3 alkoxy, and Cl- 3 alkyl;
R
5 is methoxy; A is or -CONH-; a is 1, 2 or 3; B is -NHCO-, -CONH, -NHC(O)O-, NHCONH- or a single direct bond; bis0, 1 or2; D is piperazinyl or morpholinyl or piperidinyl, each ring being optionally substituted by 1 or 2 substituents selected from C 1 .4alkyl, C 2 4 alkanoyl, carbamoyl, cyanoC1.
3 alkyl, hydroxyCi-3alkyl, carboxyCi-salkyl and aminoCi- 3 alkyl;
R
7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
Another further preferred class of compound is of the formula (III) wherein: R' R 2 and R 3 are all methoxy;
R
4 and R 6 are independently selected from hydrogen, hydroxy, methoxy and methyl;
R
5 is methoxy; A is or -CONH-; a is 2 or 3; WO 02/08213 PCT/GB01/02964 B is -NHCO-, -CONH or a single direct bond; bis 0or 1; D is piperazino or morpholino, each ring being optionally substituted by 1 or 2 substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2-hydroxyethyl;
R
7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
In another aspect the invention relates to a compound of the formula (IV): MeO MeO OMe
(IV)
wherein a, b, A, B and D are as hereinabove defined for formula or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
Another preferred class of compounds is that of the formula (IV) wherein: A is or -CONH-; ais2or3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is piperazino or morpholino, each ring being optionally substituted by 1 or 2 substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2-hydroxyethyl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
Another preferred class of compounds is that of the formula (IV) wherein: A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is morpholino, 4-methylpiperazin-l-yl or 4-acetylpiperazin-1-yl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
WO 02/08213 WO 0208213PCT/GB01/02964 16 Another preferred class of compounds is that of the formula (TV) wherein: A is or -CONH-; a is 2 or 3; B is -CO- or a single direct bond; b is 0; D is morpholino, 4-methylpiperazin-1-yl or 4-acetylpiperazin-l-yl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
Particular compounds of the present invention include: -3,9,10,11 -tetramethoxy-6,7-dihyclro-5H-dibenzo~a,c]cyclohepten-5-y1]-2- [2aminoacetyl amino] acetamide; 4-oxo-4- S)-3 ,9,1 10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo yl]amino]butyl disodiumn phosphate; N- [2-(irnidazol-1I-yI)ethyl]carbamoyl 1 10,11I -tetramethoxy-6,7-dihydro-5Hand 2- 10,1 1-tetramethoxy-6,7-dihvdro-5H-dibenzo yl]carbamoyloxy Iethyl disodiumn phosphate; and pharmaceutical ly-acceptable salts, solvates or pro-drugs thereof.
Further particular compounds of the present invention include: 2-morpholinoethyl N- 10,1 1-tetramethoxy-6,7-dihydro-5H-dibenzo I -methylpiperazin-4-yl)propyl N- 10,11 -tetramethoxy-6,7-dihydro-5Hdibenzo [a,c]cyclohepten-5-yl] carbamnate; 10,1 1-tetramethoxy-6,7-dihydro-5H-dibenzo[a,clcyclohepten-5-y] [2aminoacetyl amino] acetamnide; 1-acetylpiperazin-4-yl)ethyl-N-[(5S)-3,9, 10,I1-tetramethoxy-6-7-dihydro-5Hcarbamate; 10,l1-tetramethoxy-6-7-dihydro-5H-clibenzo[a,clcyclohepten-5-y] 1methylpiperazin-4-yl)-4-oxobutan-1-amide; WO 02/08213 PCT/GB01/02964 -17- 4-oxo-4-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5yl]amino]butyl disodium phosphate; N-{N-[2-(imidazol- 1-yl)ethyl]carbamoyl }-5(S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H- 3-(1 -acetylpiperazin-4-yl) propyl-N-[(5S)-3,9,10,11-tetramethoxy-6-7-dihydro-5H- N-1-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5yl]carbamoyloxy]ethyl disodiumphosphate; 4-morpholino-4-oxobutyl-N-[(5S)-3,9,10, 11-tetramethoxy-6,7-dihydro-5H-dibenzo [a-c]cyclohepten-5-yl]carbamate; and 4-(1-methylpiperazin-4-yl)-4-oxobutyl-N-[(5S)-3,9,10, 11-tetramethoxy-6,7-dihydroand pharmaceutically-acceptable salts, solvates or pro-drugs thereof.
Synthesis of Compounds of the Formula (I) Compounds of Formula may be prepared by a number of processes as generally described hereinbelow and more specifically in the Examples hereinafter. Processes for the preparation of novel compounds of formula are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
Thus according to another aspect of the invention, a compound of the Formula may be formed by deprotecting a compound of the formula wherein at least I functional group is protected. For example, amino, hydroxy, carboxy or phosphoryloxy groups may be protected during the reaction sequence used to prepare a compound of the formula Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting WO 02/08213 PCT/GB01/02964 -18group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
A suitable protecting group for a hydroxy group is, for example, an arylmethyl group (especially benzyl), a triCl.
4 alkysilyl group (especially trimethysilyl or tert-butyldimethylsilyl), an aryldi-Cl-4alkylsilyl group (especially dimethylphenylsilyl), a diarylCi-4alkylsilyl group (especially tert-butyldiphenylsilyl), a Ci.
4 alkyl group (especially methyl), a C2.4alkenyl group (especially allyl), a C1.
4 alkoxymethyl group (especially methoxymethyl) or a tetrahydropyranyl group (especially tetrahydroyran-2-yl). The deprotection conditions for the above protecting groups will necessary vary with the choice of protecting group. Thus, for an example, arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal. Alternatively a trialkylsilyl or an aryldialkylsilyl group such as tert-butydimethylsilyl or a dimethylphenylsilyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid, or with an alkali metal or ammonium fluoride such as sodium fluoride or, preferably tetrabutylammonium fluroide. Alternatively an alkyl group may be removed, for example, by treatment with an alkali metal Ci- 4 alkylsulphide such as sodium thioethoxide or, for example, by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide or, for example, by treatment with a boron or aluminium trihalide such as boron tribromide. Alternatively a C 1 .4alkoxymethyl group or tetrahydropyranyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric or trifluoroacetic acid.
Alternatively a suitable protecting group for a hydroxy group is, for example, an acyl group, for example a C2- 4 alkanoyl group (especially acetyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
A suitable protecting group for an amino, imino or alkylamino group is, for example, an acyl group, for example a C2-4alkanoyl group (especially acetyl), a Ci- 4 alkoxycarbonyl) group (especially methoxycarbonyl), ethoxycarbonyl or tert-butoxycarbonyl), an arylmethoxycarbonyl group (especially benzyloxycarbonyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups necessarily vary with WO 02/08213 PCT/GB01/02964 -19the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl, alkoxycarbonyl or aroyl group may be removed for example, by hydrolysis with a suitable base such as alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid, and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a C 1 4 alkyl group (especially methyl or ethyl) which may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide; or for example, a tert-butyl group which may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid.
The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March, published by John Wiley Sons 1992, for general guidance on reaction conditions and reagents and to Protective Groups in Organic Synthesis, 2 nd Edition, by T. Green et al., also published by John Wiley Son, for general guidance on protecting groups.
In the following process description the symbols R' R 7 A, B, D, Ra R b a and b are to be understood to represent those groups described above in relation to formulae and (II) unless otherwise stated.
A compound of the formula or a compound of the formula wherein at least 1 functional group is protected, may be prepared using one of the following processes: a) reacting a compound of the formula (X) 3
NH(R
7 RR 4 R 1
R
with a compound of the formula (XI): L' A [CH(Ra)1a-B-[CH Rb )b-D (XI) WO 02/08213 PCT/GB01/02964 wherein Ll is a leaving group; or b) converting one compound of the formula into another compound of the formula or c) when a phosphoryloxy group is desired, reacting the corresponding hydroxy compound with a phosphoramidite; wherein any functional groups are optionally protected.
and thereafter if necessary: i) converting a compound of formula into another compound of formula ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt, solvate or pro-drug thereof.
The reaction between a compound of the formula and a compound of the formula L A [CH(Ra Rb )b-D is conveniently performed under standard acylation or sulphonylation conditions. L' is usually halogeno, for example chloro or bromo, hydroxy, mesyloxy, tosyloxy or an 'activated' hydroxy group. The precise conditions depending largely upon the nature of A.
For example, when is L' may be hydroxy and the reaction carried out in the presence of coupling agent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)- 3-ethylcarbodiimide. Optionally, a base may be used, for example an organic base such as triethylamine. Suitable solvents are usually aprotic solvents, for example dimethylformamide, or chlorinated solvents, for example trichloromethane or dichloromethane. The temperature is usually in the range of about -30 0 C to about 60 0 C, conveniently at or near ambient temperature.
When is L' is usually an "activated" hydroxy group. That is a group which acts as a leaving group in the same way as hydroxy, but is more labile. It can be formed in situ. An example of an activated hydroxy group is 4-nitrophenoxy, which can be formed by reacting a hydroxy group (HO-[CH(R a with 4nitrophenylchloroformate. This reaction is usually carried out in an organic solvent such as dichloromethane, acetonitrile or tetrahydrofuran, in a temperature range of about -20 0 C to the reflux temperature of the solvent. In addition, organic base such as triethylamine or Nmethylmorpholine is normally present. Alternatively, a compound of the formula can be reacted with 4-nitrophenylchloroformate and the resulting intermediate reacted with WO 02/08213 PCT/GB01/02964 -21- HO-[CH(Ra)]a-B-[CH(Rb)]b-D under similar conditions to those described above for the reaction of a compound of the formula with a compound of the formula
L
2 -[CH(Ra)]a-B-[CH(Rb)]b-D wherein L 2 is 4-nitrophenoxy.
When is -CON(R 8 L' is preferably halogeno, particularly chloro. Alternatively when is -CONH-, a compound of the formula can be reacted with an isocyanate of the formula C=N-[CH(Ra)]a These reactions are conveniently carried out in the presence of a base, particularly an organic base, such as triethylamine, pyridine or Nmethylmorpholine, in a solvent such as an ether solvent, for example tetrahydrofuran, or in a chlorinated solvent, for example dichloromethane, at a temperature in the range from about 20 0 C to the reflux temperature of the solvent. Alternatively, a compound of the formula (X) can be reacted with 4-nitrophenylchloroformate and the resulting intermediate reacted with Ri7-NH 2 under similar conditions to those described above for the reaction of a compound of the formula with a compound of the formula L 2 -[CH(Ra)]a-B-[CH(Rb)]b-D wherein L 2 is 4-nitrophenoxy.
When is of the formula -SO 2 or -S02N(R 8 L' is preferably halogeno, for example chloro. The reaction is conveniently carried out in the presence of a base such as dimethylaniline, in a chlorinated solvent such as trichloromethane and at a temperature in the range of -20 0 C to about 60 more preferably in pyridine, at a temperature in the range from 0 C to about 60 C.
A compound of formula may be prepared from another compound of formula by chemical modification. Examples of chemical modifications include standard alkylation, arylation, heteroarylation, acylation, sulphonylation, phosphorylation, aromatic halogenation and coupling reactions. These reactions may be used to add new substituents or to modify existing substituents. Alternatively, existing substituents in compounds of formula may be modified by, for example, oxidation, reduction, elimination, hydrolysis or other cleavage reactions to yield other compounds of formula Thus for example a compound of formula containing an amino group may be acylated on the amino group by treatment with, for example, an acyl halide or anhydride in the presence of a base, for example a tertiary amine base such as triethylamine, in for example, a solvent such as a hydrocarbon solvent e.g. dichloromethane at a temperature in the range for example -30°C to 120 0 C, conveniently at or near ambient temperature.
WO 02/08213 PCT/GB01/02964 -22- In another general example of an interconversion process, an amino group in a compound of formula may be sulphonylated by treatment with, for example, an alkyl or aryl sulphonyl chloride or an alkyl or aryl sulphonic anhydride in the presence of a base, for example a tertiary amine base such as triethylamine, in for example a solvent such as a hydrocarbon solvent e.g. dichloromethane, at a temperature in the range for example -30°C to 120 0 C, conveniently at or near ambient temperature.
In a further general example, a compound of formula containing a hydroxy group can be converted into the corresponding dihydrogenphosphate ester by treatment with for example di-tert-butyl diisopropylphosphoramidite or di-tert-butyl diethylphosphoramidite in the presence of a suitable catalyst, for example tetrazole. A solvent such as an ether solvent, for example tetrahydrofuran can be used. The reaction is usually carried out at a temperature in the range -40 0 C to 40 0 C, conveniently at or near ambient temperature, followed by treatment with an oxidising agent for example 3-chloroperoxy benzoic acid at a temperature in the range -78 0 C to 40 0 C preferably -40°C to 10 0 C. The resulting intermediate phosphate triester is treated with an acid, for example trifluoroacetic acid, in a solvent such as a chlorinated solvent e.g. dichloromethane at a temperature in the range -30'C to 40 0
C,
conveniently at or near 0'C, to give the compound of formula containing a dihydrogenphosphate ester.
In a further general example a compound of formula containing an amide can be hydrolysed by treatment with for example an acid such as hydrochloric acid in a solvent such as an alcohol, for example methanol at an elevated temperature conveniently at the reflux temperature.
In another general example an alkoxy group may be converted to the corresponding alcohol (OH) by reaction with boron tribromide in a solvent such as a chlorinated solvent e.g.
dichloromethane at a low temperature e.g. around -78 0
C.
In a further general example a compound of formula may be alkylated by reaction with a suitable alkylating agent such as an alkyl halide, an alkyl toluenesulphonate, an alkyl methanesulphonate or an alkyl triflate. The alkylation reaction can be carried out in the presence of a base, for example an inorganic base such as a carbonate e.g. caesium or potassium carbonate, a hydride such as sodium hydride or an alkoxide such as potassium tbutoxide, in a suitable solvent such as an aprotic solvent e.g. dimethylformamide or an ether solvent such as tetrahydrofuran, at a temperature of around -10 0 C to 80 0
C.
WO 02/08213 PCT/GB01/02964 -23- In a further example, an unsubstituted ring nitrogen in a saturated heterocyclic ring may be acylated using similar reaction conditions to those described above for the acylation of an amino group.
Synthesis of Intermediates A compound of the formula may be known or prepared according to processes described in International Patent Application No. PCT/GB98/01977.
A compound of the formula (XI) may be known or prepared by methods known in the art. For example, when A is of the formula and L' is 4-nitrophenyloxy, the compound of the formula (XI) may be formed by reacting a compound of the formula:
HO-[CH(R
7 B [CH(R 7 )b-D with 4-nitrophenyl chloroformate, in the presence of a base, preferably an organic base such as triethylamine, in an inert organic solvent such as dichloromethane. The reaction is usually carried out in a temperature range of -30 0 C to 60 OC, most commonly at around ambient temperature.
Acid addition salts of the compounds of formula are prepared in a conventional manner by treating a solution or suspension of the free base of a compound of formula with about one equivalent of a pharmaceutically acceptable acid. Salts of compounds of formula derived from inorganic or organic bases are prepared in a conventional manner by treating a solution or suspension of the free acid of a compound of formula with about one equivalent of a pharmaceutically acceptable organic or inorganic base. Alternatively both acid addition salts and salts derived from bases may be prepared by treatment of the parent compound with the appropriate ion-exchange resin in a standard fashion. Conventional concentration and recrystallistion techniques are employed in isolating the salts.
Compounds according to the invention are able to destroy vasculature that has been newly formed such as tumour vasculature while leaving unaffected normal, mature vasculature. The identification of compounds which selectively, and preferably potently, damage newly-formed vasculature is desirable and is the subject of the present invention. The ability of the compounds to act in this way may be assessed, for example, using one or more of the procedures set out below: WO 02/08213 PCT/GB01/02964 -24- Activity against tumour vasculature measured by radioactive tracer This assay demonstrates the ability of compounds to damage selectively tumour vasculature.
Subcutaneous CaNT tumours were initiated by injecting 0.05ml of a crude tumour cell suspension, approximately 106 cells, under the skin overlying the rear dorsum of 12-16 weekold mice. The animals were selected for treatment after approximately 3-4 weeks, when their tumours reached a geometric mean diameter of 5.5-6.5 mm. Compounds were dissolved in sterile saline and injected intraperitoneally in a volume of 0.1 ml per 10g body weight.
Tumour perfusion was measured 6 hours after intraperitoneal administration in tumour, kidney, liver, skin, muscle, gut and brain by the 86RbCl extraction technique (Sapirstein, Amer. Jnl. Physiol., 1958, 193, 161-168). Tissue radioactivity measured 1 minute after an intravenous injection of 8 6 RbCI was used to calculate relative blood flow as a proportion of cardiac output (Hill and Denekamp, Brit. Jnl. Radiol., 1982, 55, 905-913). Five animals were used in control and treated groups. Results were expressed as a percentage of the blood flow in the corresponding tissues in vehicle treated animals.
Activity against tumour vasculature measured by fluorescent dye This assay demonstrates the ability of compounds to damage tumour vasculature.
Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the fluorescent dye Hoechst 33342 according to the method of Smith et al (Brit. Jnl.
Cancer 1988, 57, 247-253). Five animals were used in control and treated groups. The fluorescent dye was dissolved in saline at 6.25mg/ml and injected intravenously at 24 hours after intraperitoneal drug treatment. One minute later, animals were killed and tumours excised and frozen; 10gm sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence. Blood vessels were identified by their fluorescent outlines and vascular volume was quantified using a point scoring system based on that described by Chalkley, (Jnl. Natl. Cancer Inst., 1943, 4, 47-53).
All estimates were based on counting a minimum of 100 fields from sections cut at the 3 different levels.
The ability of the compounds to bind to preparations of mammalian tubulin can be evaluated by a number of methods available in the literature, for example by following temperature initiated tubulin polymerisation by turbidity in the absence and presence of the compound (for example O.Boye et al Med. Chem. Res., 1991, 1, 142-150).
WO 02/08213 PCT/GB01/02964 The activity of N-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5H- Fernholz Justus Liebigs Ann., 1950, 568, 63-72), against tumour vasculature was measured by the fluorescent dye method described above.
This compound decreased perfused vascular volume by 88% relative to control when dosed at 50mg/kg intraperitoneally. The IC 5 o of this compound in a tubulin polymerisation assay was 58 micromolar (O.Boye etal Med. Chem. Res., 1991, 1, 142-150).
HUVEC detachment assay This assay examined the effects of compounds on the adherence of HUVECs to tissue culture plasticware.
HUVECs were plated in 0.2% gelatin-coated 12 well tissue culture plates at a concentration of 3x10 4 cells per well in Iml TCS medium. After 24 hours, when the cells were at -30% confluency, the cells were dosed with compound for 40 minutes at 37 0 C,
CO
2 After this incubation the medium containing drug was pipetted off, and the cells were then gently washed in 2mls of HBSS (Hanks' Balanced Salt Solution purchased from Life Technologies Ltd, Paisley UK; Catalogue 24020-083) to remove any detached cells. The washing solution was then removed, and the adherent cells remaining were trypsinised using 300tl of Ix Trypsin-EDTA solution (Life Technologies Ltd, Paisley, UK; Catalogue 43500- 019) at ambient temperature for 2 minutes. The trypsinised cells were then made up to lml with TCS Biologicals medium, then centrifuged at 2000rpm for 2 minutes. The cell pellet was then resuspended in a volume of 50ptl of TCS Biologicals medium. Total cell counts were obtained by counting the cells on a haemocytometer. The amount of cell detachment was calculated by comparing the number of cells remaining attached following treatment with the number in undosed control wells.
Hras5 necrosis model NIH 3T3 fibroblasts transfected with Harvey ras, clone 5, (Hras5 cells) were kept in continual passage in Dulbecco's modifed Eagles medium (DMEM) containing 10% foetal bovine serum (FBS) and 1% glutamine, at 37°C in a humidified incubator gassed with carbon dioxide and 92.5% oxygen. Cells were implanted subcutaneously into the left flank of male nude mice (8-10weeks of age) at an inoculum of 2 x 105 cells/mouse. Tumours were measured using calipers and randomised into groups of 2-4 mice between days 9-14 after implant. Mice were dosed with compounds, either intravenously or intraperitoneally, once on WO 02/08213 PCT/GB01/02964 -26day of randomisation and culled 24 hours after dosing. Compounds were dissolved in hydroxypropyl beta cyclodextrin in physiological saline at pH 7 and dosed in a volume of 0.lml per 10g body weight. Tumours were excised, weighed and placed in buffered formalin.
Area of necrosis in individual tumours was assessed from a haematoxylin/eosin stained-slide by a pathologist and scored from 0, meaning no significant change, to 10, meaning 91-100% necrosis. The activity of examples 5 and 7 (described hereinafter) against tumour vasculature was measured by the fluorescent dye method described hereinabove. Example 1 scored 6.0 at 100m/kg and example 4 scored 3.2 at According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula as defined hereinbefore or a pharmaceutically acceptable salt, solvate or pro-drug thereof, in association with a pharmaceutically acceptable excipient or carrier.
The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for nasal administration or administration by inhalation, for example as a powder or solution, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.
The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000mg per square metre body area of the animal, i.e.
approximately 0.1-100mg/kg. A unit dose in the range, for example, 1-100mg/kg, preferably 1-50mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250mg of active ingredient.
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity WO 02/08213 PCT/GB01/02964 -27of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
According to a further aspect of the present invention there is provided a compound of the formula or a pharmaceutically acceptable salt, solvate or pro-drug thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
A further feature of the present invention is a compound of formula or a pharmaceutically acceptable salt, solvate or pro-drug thereof, for use as a medicament, conveniently a compound of formula or a pharmaceutically acceptable salt, solvate or pro-drug thereof, for use as a medicament for producing a vascular damaging effect in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided the use of a compound of the formula or a pharmaceutically acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human being.
According to a further feature of the invention there is provided a method for producing a vascular damaging effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula or a pharmaceutically acceptable salt, solvate or pro-drug thereof as defined hereinbefore.
According to a further aspect of the present invention there is provided a compound of formula or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, when dosed in divided doses (also known as split doses) produces a greater anti-tumour effect than when a single dose is given.
Anti-tumour effects of a method of treatment of the present invention include but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to re-growth of tumour on cessation of treatment, slowing of disease progression. It is expected that when a method of treatment of the present invention is administered to a warm-blooded animal such as a human, in need of treatment for cancer involving a solid tumour, said method of treatment will produce an effect, as measured by, for example, one or more of: the extent of the anti-tumour effect, the response rate, the time to disease progression and the survival rate.
WO 02/08213 PCT/GB01/02964 -28- According to a further aspect of the present invention there is provided a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of formula or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of formula or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition.
According to a further aspect of the present invention there is provided a medicament comprising two or more fractions of doses of a compound of formula or pharmaceuticallyacceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses for use in a method of treatment of a human or animal body by therapy.
According to a further aspect of the present invention there is provided a kit comprising two or more fractions of doses of a compound of formula or pharmaceuticallyacceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses: According to a further aspect of the present invention there is provided a kit comprising: a) two or more fractions of doses of a compound of formula or pharmaceuticallyacceptable salt, solvate or pro-drug thereof, which together add up to a total daily dose, in unit dosage forms for administration in divided doses; and b) container means for containing said dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) two or more fractions of doses of a compound of formula or pharmaceuticallyacceptable salt, solvate or pro-drug thereof, which together add up to a total daily dose, together with a pharmaceutically acceptable excipient or carrier, in unit dosage forms; and b) container means for containing said dosage forms.
WO 02/08213 PCT/GB01/02964 -29- According to a further aspect of the present invention there is provided the use of compound of formula or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided the use of a compound of formula or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided the use of a compound of formula or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.
Divided doses, also called split doses, means that the total dose to be administered to a warm-blooded animal, such as a human, in any one day period (for example one 24 hour period from midnight to midnight) is divided up into two or more fractions of the total dose and these fractions are administered with a time period between each fraction of about greater than 0 hours to about 10 hours, preferably about 1 hour to about 6 hours, more preferably about 2 hours to about 4 hours. The fractions of total dose may be about equal or unequal.
Preferably the total dose is divided into two parts which may be about equal or unequal.
The time intervals between doses may be for example selected from: about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours and about 6 hours.
The time intervals between doses may be any number (including non-integers) of minutes between greater than 0 minutes and 600 minutes, preferably between 45 and 375 minutes inclusive. If more than two doses are administered the time intervals between each dose may be about equal or unequal.
Preferably two doses are given with a time interval in between them of greater than or equal to 1 hour and less than 6 hours.
More preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than 5 hours.
Yet more preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than or equal to 4 hours.
WO 02/08213 PCT/GB01/02964 Particularly the total dose is divided into two parts which may be about equal or unequal with a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.
More particularly the total dose is divided into two parts which may be about equal with a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.
For the avoidance of doubt the term 'about' in the description of time periods means the time given plus or minus 15 minutes, thus for example about 1 hour means 45 to 75 minutes, about 1.5 hours means 75 to 105 minutes. Elsewhere the term 'about' has its usual dictionary meaning.
The antiangiogenic treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the antiangiogenic treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may include the following categories of therapeutic agent: other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin cav3 function, angiostatin, endostatin, razoxin, thalidomide) and including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) (for example those described in International Patent Applications Publication Nos. WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 the entire disclosure of which documents is incorporated herein by reference); (ii) cytostatic agents such as antioestrogens (for example tamoxifen,toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator WO 02/08213 PCT/GB01/02964 -31receptor function) and inhibitors of growth factor function, (such growth factors include for example epidermal growth factor (EGF), platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); (iii) biological response modifiers (for example interferon); (iv) antibodies (for example edrecolomab); and antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); enzymes (for example asparaginase); thymidylate synthase inhibitors (for example raltitrexed); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan, irinotecan).
As stated above the compounds defined in the present invention are of interest for their vascular damaging effects. Such compounds of the invention are expected to be useful in the prophylaxis and treatment of a wide range of disease states where inappropriate angiogenesis occurs including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.
In addition to their use in therapeutic medicine, the compounds of formula and their pharmaceutically acceptable salts, solvates or pro-drugs are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of vascular damaging agents in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
WO 02/08213 PCT/GB01/02964 -32- It is to be understood that where the term "ether" is used anywhere in this specification it refers to diethyl ether.
The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated: evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration; (ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen; (iii) yields are given for illustration only and are not necessarily the maximum attainable; (iv) the structures of the end-products of the formula were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet; intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis; Abbreviations 4-Dimethylaminopyridine DMAP 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDCI Dimethyl sulphoxide DMSO Trifluoroacetic acid TFA WO 02/08213 PCT/GB01/02964 -33- Example 1 -3.9,10,11-Tetramethoxv-6.7-dihydro-5H-dibenzo[a,ccyclohepten-5-vll-2-[2aminoacetylaminolacetamide O NHBOC ON 0- 0- A solution of N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]- 2-[2-(butoxycarbonylamino)acetylamino]acetamide (0.9 g 0.64 mmol) in dichloromethane (6 ml) was treated with TFA (6 ml) at ambient temperature for 0.5 hour. After evaporation to dryness, the residue was neutralised to pH 6.5 with solid sodium hydrogen carbonate and purified on reverse phase silica eluting with a gradient of 30-40 methanol ammonium carbonate buffer (2 g 1, pH The appropriate fractions were evaporated to dryness and triturated in ether to give the title compound.
Yield: 65 'H NMR (DMSO-d 6 1.88-2.21 3H) 2.58 partially obscured by DMSO peak 1H); 3.10 2H) 3.46 3H) 3.79 3H) 3.82 3H) 3.83 3H) 3.84 3H) 4.47-4.58 1H) 6.77 1H) 6.87 (dd, 1H) 6.91 1H); 7.25 1H) 8.06 1H) 8.41 (d, 1H).
MS-ESI: 444 [MH] Elemental analysis Found C 59.14 H 6.44 N 9.08
C
23
H
2 9
N
3 0 6 1.2 H 2 0 Requires C 59.39 H 6.80 N 9.03 The starting material was prepared as follows: I o O H O N o- 0- A solution of (5S)-3,9,10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5ylamine [Collect. Czech. Chem. Commun. 1999, 64(2), 217-228] (0.329 g; 1.36 mmol), WO 02/08213 WO 0208213PCT/GB01102964 34.
EDGI (0.230 g; 1.2 mmol); DMAP (0.025 g, 0.2 mmol) and 2 [2-(tert-butoxycarbonyl amino) acetylamino] acetic acid 189 g 1.2 mmol) in dichioromethane was stirred under argon atmosphere overnight. The resulting precipitate was filtered and washed with ether to give N- 10,11 -tetramethoxy-6,7-dihydro-SH-dibenzo cyclohepten-5-yl]-2-[2- (hutoxycarbonylamino)acetyl amino] acetamide as a white solid.
Yield: 65 'H NMR (DMSO-d 6 1.33 9H1) 1.94-2.24 (in, 3H) 2.97-3.08 (in, III) ;3.35 3H) 3.56 3H) 3.7 1-3.77 (mn, lH) 3.75 3H) 3.78 3H1) 3.80 314) 4.48-4.59 (in, lH) ;6.79 I1H) 6.87 (dd, I H) 6.93 IlH) ;7.14 I H) 7.25 I1H) 8. 17 I1H) 8.21 (d, 11-).
MS-ESI: 544 [MH]V Example 2 4-Oxo-4-[(5S)-3,9,1O,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,clcyclohepten-5yllaminolbutyl disodium phosphate 00 0 0 ~10 ONa A solution of 10,11 -tetramethoxy-6,7-dihydro-5H-dibenzola,c]cyclohepten-5-yl] 4-[di(tert-butoxy)phosphoryloxy]butanamnide (0.529g; 0.892 inmol) in a mixture of (12N) HCl ml) and dioxan (25 ml) was stirred under argon atmosphere for 4 hours. After evaporation of the dioxan, the pH was adjusted at 7.2 with sodium hydroxide solution (2N) and the residue purified on HP20SS resin eluting with a 0-40 gradient of methanol/water to give the title compound after freeze drying.
Yield: 75 'H NMR (DMSO-d 6 :1.71-2.36 (mn, 7H) 2.58 partially obscured by DMSO peak (in, IH); 3.49 3H1) ;3.78 -3.85 (mn, 1 lH) 5.20 (dd, lH) 5.00 11-) 6.77 11-) 6.88 (dd, 1H) 6.91 I H) ;6.26 I H).
WO 02/08213 WO 0208213PCT/GB01/02964 35 The starting material was prepared as follows:
I
-0 0 H 10,1 1-tetramethoxy-6,7-dihydro-5H-dibenzo La,cJcyclohepten-5-yl] -4-[di-(tertbutoxy)phosphoryloxy]butanamide was prepared using a similar method to that of Example 1 by reacting 10,1 1-tetramethoxy-6,7-dihydro-5H-dibenzo [a,clcyclohepten-5-ylai nie with 4- [di(tert-butoxy)phosphoryloxy]butanoic acid.
Yield: 89 'H NMR (DMSO-d,): 1.40 18H) 1.80 2H) 1.82-1.94 (in, 1H) 2.00-2.20 (in, 2H; 2.23-2.33 (in, 2H) 2.52-2.58 (in, lH) 3.48 3H) 3.78 3H) 3.80-3.85 (mn, 8H) 4.50- 4.59 (in, IH); 6.78 1H) 6.89 (dd, 1H) 6.90 lH) 7.26 1H) 8.42 1H).
Example 3 N-{N-[2-(Imidazol-1-vl)ethvllcarbamoll-5(S)-391.1 1-tetramethoxv-6,7-dihydro-SH- 2 HN-"
N
00 A solution of 10,1 l-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5ylainine (0.263 g 0.8 iniol), 4-nitrophenol chiorofornate (0.177 g 0.88 mmol) and triethylamine 123 ml 0.88 minol) in dichloroinethane was stirred under argon atmosphere for 1 hour. 2-(Imidazol-1-yl)ethylamine (0.145 ml 1.2 mmol) was added. After stirring for 2 hours, the mixture was evaporated to dryness and the residue purified on reverse phase silica WO 02/08213 WO 0208213PCT/GB01/02964 36 eluting with a 40-60 gradient of methanol ammonium carbonate buffer (2 g/l, pH 7) to give the title compound after evaporation and trituration in ether.
Yield: 52 'H NMR (DMSO-d 6 1.66-1.77 (in, IH) 1.97-2. 10 (in, 1 H) 2.13-2.25 (in, I H) 2.53 partially obscured by DMSO peak (mn, 1H) 3.12-3.32 (in, 2H) 3.47 3H) 3.77 3H); 3.79 3H) 3.83 1H) 3.94 3H1); 4,32-4.42 (in, IH) 5.97 IH) 6.63 1H) 6.77 III) 6.83-6.92 (in, 3H) 7.11 1H) ;7.24 111); 7.54 IH).
MS-ESI: 481 [MH] t Elemental analysis Found C 64.68 H 6.89 N 11.55
C
2 6
H
32
N
4 0 5 Requires C 64.98 H 6.71 N 11.66 Example 4 2-{N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a~c]cyclohepten-5yllcarbamovloxylethyl disodium phosphate OBnOa 0i O-Pi-O OBn ONa A solution of 2- [di-(benzyloxy)phosphoryloxy]ethyl 10,11 -tetramethoxy-6,7- (0.576 g 0.85 inmol) in solution in methanol (10 ml) and ethyl acetate (5 ml) was hydrogenated in the presence of 10 C/Pd 165 mg) for 4 hours. After filtration on celite and evaporation, the residue was purified on SS resin eluting with a 0-80 gradient of methanol/di stilled water. The pH of the corresponding fractions was adjusted at 8 with aqueous sodium hydroxide solution after evaporation of the methanol. After freeze drying the title compound was obtained as a white solid.
Yield: 83 1H NMR (DMSO-d 6 TFA-d) :1.85-1.97 (in, 1H) 1.98-2.09 (mn, 1H) 2.13-2.27 (in, 1H); 2.42-2.52 (mn, I H) 3.48 3H) 3.79 3H) 3.80 3H) 3.84 3H) 3.98 (in, 2H); WO 02/08213 WO 0208213PCT/GB01/02964 37 4.03-4.18 (in, 2H) 4.04-4.17 (in, 2H) 4.24-4.35 (in, I1H) ;6.77 I H) ;6.89 (dd, I H) ;6.96 I1H) 7.27 ILH).
MS-ESI: 498 [MH]' The starting material was prepared as follows: Bn U0..OI OBn I "N 2 )r N 0 Bn 0- 0- 4-Nitrophenyl chloroformate (1.01 g 5.04 mmol) was added at 0 0 C under argon atmosphere to a solution of 2-Ildi (benzyloxy)phosphoryloxy]ethanol (1.62 g 5.09 minol) and triethylamine (0.7 ml 5 inmol) in dichloromethane (20 ml). The mixture was stirred at ambient temperature for 30 minutes, evaporated and purified by flash chromatography, eluting with petroleum ether ethyl acetate (40/60) to give 2-[di(benzyloxy)phosphoryloxy] ethyl 4-nitrophenyl carbonate.
Yield: 45 1 HINMR (CDC1 3 4.21-4.30 (in, 2H) 4.41 (in, 2H4) 5.01-5.15 (in, 4H) 7.29-7.42 (in, 12H) 8.25 2H).
A solution of (5S)-3 ,9,1 10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,cjcyclohepten-5ylamine (0.329 1 iniol) and 2-[di-(benzyloxy)phosphoryloxy] ethyl 4-nitrophenyl carbonate (0.633 g 1.3 iniol) in acetonitrile (8 ml) was heated at 65'C, under argon atmosphere for 8 hours. After evaporation to dryness, the residue was purified by flash chromatography eluting with a 50-80 gradient of ethyl acetate petroleum ether to give 2-[di(benzyloxy) phosphoryloxyl ethyl 10,1 1-tetramethoxy-6,7-dihydro-5Hdibenzo Yield: 85 'H NMR (DMSO-d 6 1.81-1.93 (in, I H) 1.94-2.06 (in, I1H) 2.06-2.20 (mn, 1H) 2.40-2.52 (mn, I1H) 3.43 3H) 3.73 3H) 3.77 3H) ;3.92 3H) 4-11 (in, 4H) 4-20-4.33 (mn, WO 02/08213 WO 0208213PCT/GB01/02964 38- 5.02 4H); 6.76 1H); 6.86 -dd, III) 6.93 1H) 7.25 (di, 111). 7.35 1OH); 7.99 (di, 11-).
Example 2-Morpholinoethyl N- [(5S)-3,9..10,11-tetramethoxv-6,7-dihydro-5H-dibenzo 1) C2OC~
ND
0 0 0 2) 2)HO~N) 0 A solution of 10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,clcyclohepten-5ylamine [Collect. Czech. Chem. Commun. 1999, 642) 217-228] (0.263 g; 0.8 mmol), 4-nitrophenyichioroformate (0.177 g 0.88 mmol) and triethylamine (0.123 ml 0.88 mmol) in acetonitrile (5 ml) was stirred under argon atmosphere for 2 hours at ambient temperature; 4-(2-hydroxyethyl)morpholine 145 ml 1.2 mmol) in solution in acetonitrile (2 ml) was then added to the above solution. The mixture was heated at 60'C overnight. After evaporation to dryness, the residue was purified by flash chromatography, eluted with ethanol/dichloromethane (4/96) to give the title compound.
Yield: 64 'H NMR Spectrum (DMSO-d 6 AcO-d 4 1.82-2.31 (in, 3H1); 2.44 (in, 4H) 2.49 (mn, 2H1); 2.57 partially obscured by DMSO peak (in, 1H) 3.47 3H) ;3.56 (in, 4H) 3.78 3H) 3.79 3H1) ;3.83 3H1) 4.03 (in, 2H) 4.17-4.33 (in, lH) ;6.76 111); 6.88 (dci, IH) 6.93 (di, 1H) ;7.26 (ci, lH) 7.86 11-).
MS-ESI: 487 [MH]+ Elemental analysis: Found C 63.38 H 7.04 N 5.74
C
26
H
34
N
2 0 7 ,0.3 H 2 0 Requires C 63.48 H 7.09 N 5.69 WO 02/08213 WO 0208213PCT/GB01/02964 39 Example 6 3-(1-Methylpiperazin-4-vl)pronyI N-[(5S)-3,9,10,1 1-tetramethoxy-6..7-dihydro-5Hdibenzo Ia,clcvclohepten-5-yll carbamnate 0 -0 N NH 2
NNN
0-0 0~0- Using a similar procedure to that described for Example 5, 10,11 -tetramethoxy-6,7was reacted with 4-(3-hydroxypropyl)- 1methylpiperazine to give the title compound.
Yield 40 'H NMR (DMSO-d 6 1.62-2.44 (in, 20H) 2.54 partially obscured by DMSO peak (mn, 1H); 3.46 3H) 3.77 3H) 3.78 3H) 3.82 3H) 6.78 I H) 6.89 (dd, IlH) 6.93 (d, 1H) 7.27 I H) 80 IlH).
MS-ESI: 514 [MH]+ Elemental analysis: Found C 65.42 H 7.54 N 8.18
C
28 H4 39
N
3 0 6 Requires C 65.48 H 7.65 N 8.18 Example 7 2-(l-Acetylpiperazin-4-vl)ethyl-N-[(5S)-3,9,10,11-tetramethox-v-6-7-dihyvdro-5Hcarbamate 0~N-) 0- A solution of 2-(piperazin-4-y])ethyl-N-[(5S)-3,9, 10,11 -tetramethoxy-6-7-dihydro-5H- (0.255 g 0.525 rnmol), acetyl chloride (0.038 ml; 0.53 mmol) and triethylamine (0.073 ml 0.525 mmol) in dichioromethane (10 ml) was stirred at ambient temperature under argon atmosphere for 2 hours. After evaporation to WO 02/08213 WO 0208213PCT/GB01/02964 dryness, the residue was purified by flash chromatography, eluting with dichhloromethane/ethanol (93/7) to give the title compound.
Yield: 90 'H NMR (DMSO-d,): 1.81-2.32 (in, 3H); 1.97 3H) 2.33 (in, 2H) 2.40 (in, 2H) 2.47 partially obscured by DMSO peak (in, 2H) 2.58 partially obscured by DM80 peak (in, 1H); 3.38 (in, 4H); 3.46 3H) 3.77 (in, 3H) 3.80 3H) 3.82 3H) 3.92-4.10 (in, 2H); 4.20-4.30 (in, 1H) 6.77 LH) 6.88 (dd, 1H) 6.92 1H) 7.25 IH) 7.87 111).
MS-ESI: 528 [MH]+ Elemental analysis: Found C 63.21 H 7.30 N 7.86
C
28
H
37
N
3 0 7 Requires C 63.52 H 7.08 N 7.94 The starting material was prepared as follows
INH
2
D
boc/- 0 r- NT 0~ 2-(l1-tert-Butoxycarbonylpiperazin-4-yl)ethyl-N- 10,1 1-tetramethoxy-6,7-dihydro- 5H-dibenzo[a,clcyclohepten-5-yl~carbamate was prepared using a similar method to that described for Example 1, but using tert-butoxycarbonyl)piperazin-4-yllethanol.
Yield: 75 'H NMR (DMS0-cl 6 1.78-1.94 (in, 1H) 1.95-2.07 (in, lH) 2.10-2.23 (in, 1H) 2.30 (in, 4H) 2.38-2.53 (in, 3H) ;2.65 2H) 3.46 3H) 3.77 3H) 3.78 3H) 3.82 3H); 3.99 2H) 4.20-4.32 (in, 1H) 6.77 LH) 6.88 (dd, 1H) 6.92 IH) 7.25 IH); 7.86 1H).
1- tert-Butoxycarbonylpiperazin-4-yl)ethyl-N-[(5S)-3 10,1 1-tetramethoxy-6,7-dihydro- [a,c]cyclohepten-5-yll carbamate (0.617 g; 1.05 minol) in dichloroinethane mnl) was treated with TFA (5 ml) at ambient temperature for 1 hour. After evaporation to dryness, the residue was neutralised to pH 8 with sodium hydroxide solution and purified on reverse phase silica eluting with a gradient of 30 40 methanol ammioniumn carbonate WO 02/08213 WO 0208213PCT/GB01102964 -41buffer (2 g/l, pH 7) to give 2-(piperazin-4-yl) ethyl- N-[(5S)-3,9,1O,1 1-tetramethoxy-6-7carbamnate.
Yield: 60 'F NMR (DMSO-d 6 1.39 9H) 1.81-1.94 (in, 1H) 1.95-2.07 (in, 1H) ;2.09-2.27 (mn, 1H) ;2.34 (in, 4H) 2.52-2.64 (in, 1H) 3.28 (in, 2H) 3.36 3H1); 3.46 3H1); 3.77 (s, 3H) ;3.82 311); 3.94-4.09 (in, 211) 4.20-4.30 (in, 11H) 6.77 1H) 6.87 (dd, 1 H) 6.92 11H) 7.25 ILH) 7.8 6 I1H).
Example 8 N-[(5S)-3,9,1O.11-Tetramethoxy-6-7-dihvdro-5H-dibenzoraclcyclohepten-5-l methylpinerazin-4-yI)-4-oxobutan-I-amide -I 0
'NN
A solution of 4-(1-methylpiperazin-4-yl)-4-oxo butanoic acid (0.356 g; 1.78 mmol), EDCI (0.367 g 1.78 mmol) and DMAP (0.05 g 0.41 mmol) in dicbloromethane (30 ml) was stirred for 35 minutes under argon atmosphere. (5S)-3,9,10,1 1-Tetrainethoxy-6,7-dihydro-5H- 0.45 g 1.37 mmol) was then added and the mixture stirred at ambient temperature overnight. After evaporation of the solvent, the residue was purified by flash chromatography, eluting with dichloroinethane/ethanol (95/5) to give after evaporation and trituration in pentane, the title compound as a white solid.
Yield: 60 'H NMR (DMSO-d 6 :1.85-1.96 (in, III) 2.01-2.15 (mn, 1H); 2.16 3H) 2.22 2H); 2.26 2H) 2.33-2.42 (mn, lH) 2.47-2.53 (in, 1H) 3.35-3.46 (in, 4H) 3.46 311); 3.79 3H) 3.82 3H) 3.84 3H4) 4.44-4.56 (mn, 1H) 6.79 IH) 6.86 (dd, 1H) 6.98 (d, 1H); 7.25 111); 8.40 1H1).
MS-ESI: 512 [MH]' Elemental analysis Found C 65.51 H 7.40 N 8.19
C
2 gH 37
N
3 0 6 Requires C 65.73 H 7.29 N 8.21 WO 02/08213 WO 0208213PCT/GB01/02964 42 Example 9 3-(1-Acetylniverazin-4-vI) p~ropvl-N-[(5S)-3,9.10,1 1-tetramethoxv-6-7-diliydro-5H- INH2 0 00 000 0 A solution of (5S)-3 10,1 1-tetramethoxy-6,7-dihydro-5H-dibenzo[a,cjcyclohepten-5ylamine (0.329 g 1 mmol) and 3-(-4-acetylpiperazino)propyl 4-nitrophenyl carbonate (0.456 g; 1.3 mnmol) in acetonitrile (8 ml) was heated under argon atmosphere at 70 0 C for 6 hours. After evaporation to dryness, the residue was purified by flash chromatography eluting with dichloromnethane/ethanol (93/7) to give the title compound.
Yield: 80 'H NMR (DMSO-c1 6 1,62-2.51 (in, 12H) 1.97 3H) ;3.32-3.44 (in, 4H) 3.46 3H); 3.77 3H4) 3.78 3H) ;3.82 3H) 3.87-4.01 (in, 2H) ;4.19-4.31 (in, I1H) 6.77 IH) ;6.88 (dd, 1H) 6.92 1H) 7.25 1H) ;7.80 III).
MS-ESI: 542 [MH] 4 Elemental analysis Found C 63.48 H 7.25 N 7.72
C
29 H4 39
N
3 0 7 0.4 H 2 0 Requires C 63.46 H 7.31 N 7.66 The starting material was prepared as follows 0 NO, O 0 4-Nitrophenyl chioroformate (0.733 g; 3.63 inmol) was added to a solution of 3-(4acetylpiperazin-1I-yl) propanol [Synthesis (1997), 6, 643-6481 (0.645 g 3.46 mmol) and triethylamnine (0.51 ml 3.36 mmol) in dichioromethane (7 ml) under argon atmosphere at 0 0 C. The mixture was stirred at ambient temperature for I hour, evaporated to dryness and purified by flash chromatography, eluting with dichloromethane/ethanol (95/5) to give 3(-4acetylpiperazino)propyl 4-nitrophenyl carbonate.
WO 02/08213 WO 0208213PCT/GB01/02964 43 'H NMR (CDC1 3 1.96 (in, 2H) 2.09 3H) 2.39-2.48 (in, 4H) 2.51 2H) 3.47 3H); 3.63 2H) 3.68-3.78 (in, 2H) 4.38 2H) 7.39 2H) 8.29 2H).
Example 4-Morpholino-4-oxobutl-N-r(5S)-39.10. 11-tetramethoxv-6,7-dihydro-5H-dibenzo [a- 0 LD \I N 0 0~0 The compound was prepared using a similar method to that of Example 9, but replacing 3-(4acetylpiperazino)propyl 4-nitrophenyl carbonate by 4-morpholino-4-oxobutyl 4nitrophenylcarbonate.
Yield: 55 'HT NMR (DMSO-d 6 1.71-1.81 (mn, 2H) 1.82-1.94 (in, l IT) 1.95-2.07 I1H) 2.11-2.24 111) 2.34 2H) 2.46 (mn, 1H) 3.3 1-3.44 (in, 4H) 3.45 3H) 3.52 (in, 4H) 3.77 (s, 3H) 3.78 3H) 3-82 3H); 3.86-3.99 (mn, 2H) 4.20-4.32 (in, IH); 6.77 lT) 6.88 (dd, 1H) 6.92 1-H) 7.25 lIT) 7.80 1H).
MS-ESI: 529 [MH1+ Elemental analysis Found C 62.81 H 6.95 N 5.27
C
28
H
36
N
2 0 8 0.3 H 2 0 Requires C 62.98 H 6.91 N 5.25 The starting material was prepared using a similar method to that of example 9, starting from 4-morpholino-4-oxobutyl 4-nitrophenyl carbonate.
Yield: 92 'H NMR (CDCl 3 2.15 (mn, 2H) 2.50 2H) 3.46-3.53 (in, 2H) 3.5 1-3.75 (mn, 6H) ;3.38 2H) 7.3 3 2H) 8.29 2H).
WO 02/08213 WO 0208213PCT/GB01/02964 44- Example 11 4-(1-Methvlpiperazin-4-l)-4-oxobutl-N-(5S)-3,9,1O. 11-tetramethoxy-6..7-dihydro-5Hbarnate 0 The title compound was prepared using a similar method to that of Example 9, but replacing 3-(4-acetylpiperazino)propyl 4-nitrophenyl carbonate by 4-methylpiperazin-l-yl)-4-oxobutyl 4-nitrophenyl carbonate.
Yield: 'H NMR (DMSO-d 6 :1.75 (in, 2H) 1.81-2.07 (in, 2H) 2.08-2.40 (mn, 711); 2.15 311); 2.50-2.60 (in, ;3.22-3.56 (in, 4H); 3.45 3H) 3.77 3H) 3.78 3H) 3.82 3H) ;3.82-3.99 (in, 2H) 4.12-4.32 (in, 1H) 6.76 I1H) 6.87 (dd, LH) 6.92 1H) 7.25 (d, 111) 7.80 111).
MS-ESI: 542 [MH]+ Elemental analysis Found C 63.38 H 7.58 N 7.64
CZ
9
H
39
N
3 0 7 0.4 H 2 0 Requires C 63.46 H 7.31 N 7.66 The starting material was prepared using a similar method to that of Example 9, from 4-(4methylpiperazin-l-yl)-4-oxobutanol.
Yield: 65 'H NMR (CDCI 3 2.08-2.19 (in, 2H) 2.32 3H1); 2.35-2.46 (in, 4H) 2.49 2H) 3.51 2H) 2.66 2H) 4.3 8 2H1) 7.3 9 211); 8.29 2H).
P PERW tIuM SU5IS9516 dO-C-Z&lS o 44A
OJ)
;Z The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.
(c C 5 Throughout this specification and the claims which follow, unless the context IO requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group 0 of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Claims (6)

1. A compound of the formula Cc, N(R7)-A-[CH(Ra)]a-B- [CH (Rb)]b R 2 4 \OI R R' O o R R N wherein: R 2 and R 3 are each independently hydroxy, phosphoryloxy (-OPO 3 H 2 C 1 4 alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R 2 and R 3 are C 1 4 alkoxy; A is CO-, -SO 2 or -SO 2 N(R 8 (wherein R8 is hydrogen, Cl-4alkyl, C 1 3 alkoxyCI 3 alkyl, aminoCi. 3 alkyl or hydroxyCi 3 alkyl); a is an integer from I to 4 inclusive; RW and Rb are independently selected from hydrogen, hydroxy and amino; B is -N(R 9 -CON(R 9 -N(R 9 -N(R)SO 2 -SO 2 or a direct single bond (wherein R' and Ro 10 are independently selected from hydrogen, C 14 alkyl, C 1 .3alkoxyC. 3 alkyl, aminoC 3 alkyl and hydroxyC-.3alkyl); b is 0 or an integer from 1 to 4 inclusive, (provided that when b is 0, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino, N-(C 1 4 alkyl)amino, N,N-di(C 1 3 alkyl)amino or of the formula -Y'-(CH2)0R" or -NHCH(R' 2 )COOH; [wherein Y' is a direct single bond, -N(R" 3 -N(R or (wherein R' 3 is hydrogen, C 1 4alkyl, C.3alkoxyC 2 3alkyl, aminoC 2 3 alkyl or hydroxyC 2 3 alkyl); c is 0 or an integer from I to 4 inclusive; R" is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing I or 2 ring heteroatoms, selected independently from In -46- 0 0 0, S and N, or a 5-6-mernbered unsaturated or partially unsaturated heteroaryl group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from 0, S and N, which heterocyclic group or heteroaryl group may N bear 1 or 2 substituents selected from: oxo, hydroxy, halogeno, C 14 alkyl, C 2 4 alkanoyl, carbamoyl, N N-(C 1 4 alkyl)carbamoyl, N,N-di-(C.4alkyl)carbamoyl, hydroxyC,. 4 alkyl, C 1 4 alkoxy, cyanoC. 3 alkyl, carbamoylCl.3alkyl, carboxyCl4alkyl, aminoCI-4alkyl, N-C 1 4 alkylaminoCj 4 alkyl, di-LN-(Cl-4 alkyl)aminoCi 4 alkyl, C 1 4 alkoxyCi 4 alkyl, o CI4alkylsulphonylCI.4alkyl and R' 4 (wherein R" 4 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing I or 2 ring heteroatoms, selected independently from O, S and N, which heterocyclic group is optionally substituted by 1 or 2 substituents selected from: oxo, hydroxy, halogeno, C,. 4 alkyl, hydroxyCI-4alkyl, C 1 4 alkoxy, C 1 -4alkoxyCl- 4 alkyl and C,. 4 alkylsulphonylCi4alkyl); RIk 2 is an amino acid side chain; R 5 is C- 4 alkoxy; R 4 and R6 are each independently selected from: hydrogen, fluoro, nitro, amino, N-CI- 4 alkylamino, N,N-di-(C,4alkyl)amino, hydroxy, C, 4 alkoxy and C,. 4 alkyl; R 7 is hydrogen, C 4 alkyl, C 1 3 alkoxyCi. 3 alkyl, aminoC,. 3 alkyl orhydroxyCi 3alkyl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
2. A compound according to claim 1 where R1, R2 and R 3 are all methoxy; or a pharmaceutically acceptable salt, solvate or pro-drug thereof. 3 A compound according to claim I wherein: R'1, R 2, and R 3 are all C, 4 alkoxy; R 4 and R 6 are independently selected from hydrogen, hydroxy, C 13 alkoxy, and C. 3 alkyl; is methoxy; A is or -CONH-; a is 1,2 or 3; WO 02/08213 PCT/GB01/02964 -47- B is -NHCO-, -CONH, -NHC(O)O-, NHCONH- or a single direct bond; bis0, 1 or2; D is carboxy, sulpho, phosphoryloxy, hydroxy, amino, N-CI- 4 alkylamino, N,N-di(C 1 -4 alkyl)amino or of the formula -Y'(CH 2 )R" 1 (wherein Y 1 is -NHC(O)- or -C(O)NH-; c is 1 or 2; R" is a 5-6-membered saturated heterocyclic group (linked via nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group may bear 1 or 2 substituents selected from: C 14 alkyl, C2_4alkanoyl, carbamoyl, cyanoCI_ 3 alkyl, hydroxyCl- 3 alkyl, carboxyCi_3alkyl and aminoCl_3alkyl); R 7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
4. A compound according to claim 1 wherein: R' R 2 and R 3 are all methoxy; R 4 and R 6 are independently selected from hydrogen, hydroxy, methoxy and methyl; R 5 is methoxy; A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is carboxy, phosphoryloxy, hydroxy, amino, N-CI- 4 alkylamino, N,N-di(C 1 .4 alkyl)amino or of the formula -YI(CH 2 )cRll (wherein Y' is -NHC(O)- or -C(O)NH-; c is 1 or 2; R" is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from: Ci- 4 alkyl, C24alkanoyl, carbamoyl, cyanoC 1 .3alkyl, hydroxyC 1 3 alkyl, carboxyCl-3alkyl and aminoCl-3alkyl); R 7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof. WO 02/08213 PCT/GB01/02964 -48- A compound of formula (II): MeO NH-A-(CH2)a-B-(CH2)b-D MeO MeO OMe (II) wherein a, b, A, B and D are as defined in claim 1; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
6. A compound according to claim 5 wherein: A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; bis 0or 1; D is carboxy, phosphoryloxy, hydroxy, amino, N-C1- 4 alkylamino, N,N-di(C 1 -4 alkyl)amino or of the formula -Y'(CH 2 )cR" (wherein Y 1 is -NHC(O)- or -C(O)NH-; c is 1 or 2; R" is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from: Ci- 4 alkyl, C2- 4 alkanoyl, carbamoyl, cyanoCi-3alkyl, hydroxyCl-3alkyl, carboxyCi_3alkyl and aminoCi- 3 alkyl); or a pharmaceutically acceptable salt, solvate or prodrug thereof.
7. A compound of formula (In): (I) WO 02/08213 WO 0208213PCT/GB01/02964
49. wherein: R 2 and R 3 are each independently hydroxy, phosphoryloxy (-0P0 3 H 2 C I 4 alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R 2 and R 3 are Ci- 4 alkoxy; A is CO-, -CON(R 8 -S0 2 Or -SO 2 N(R 8 (wherein R 8 is hydrogen, C i- 4 alkyl, C I 3 alkoxyC 2 -3alkyl, aminOC 2 -jalkyl or hydroxYC 2 3 alkyl); a is an integer from 1 to 4 inclusive; W and R bare independently selected from hydrogen, hydroxy and amino; B is -N(R 9 -CON(R 9 -N(R 9 N(R 9 -N(R 9 )CON(R' 0 -N(R 9 )S0 2 -SO 2 N(R 9 or a direct single bond (wherein R 9 and R1 0 are independently selected from hydrogen, C 1 4 alkyl, CI- 3 alkoxyC 2 3 alkyl, aminoC 23 alkyl and hydroxYC 23 alkyl); b is 0 or an integer from 1 to 4 inclusive; D is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing I or 2 ring heteroatoms, selected independently from 0 and N, which heterocyclic group may bear 1 or 2 substituents selected from: oxo, hydroxy, halogeno, C 1 4 alkyl, C 24 alkanoyl, carbamoyl, N-(CI- 4 alkyl)carbamoyl, N,N-di-(C 14 alkyl)carbamoyl, hydroxyCl- 4 alkyl, C 1 4 alkoxy, cyanoCI- 3 alkyl, carbamoylCi 3 alkyl, carboxyCi .4alkyl, amninoCI 4 alkyl, N-C 1 4 alkylaminoC 1 4 alkyl, di-N-(CI- 4 alkyl)aminoC 1 4 alkyl, CI- 4 alkoxyC 14 alky1, C 1 4 alkylsulphonylCI-4alkyl and R 14 (wherein R 14 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from 0 and N, which heterocyclic group is optionally substituted by I or 2 substituents selected from: oxo, hydroxy, halogeno, CI- 4 alkyl, hydroxyQi 4 alkyl, C 14 alkoxy, CI- 4 alkoxyC 14 alkyl and C 1 4 alkylsulphonylCl 4 alkyl); R 5 is C 1 4 alkoxy; *R 4 and R 6are each independently selected from: hydrogen, halogeno, nitro, amino, N-C I 4 alkyl amino, N,N-di-(Cj- 4 alkyl)amino, hydroxy, C 1 4 alkoxy and C I 4 alkyl; R is hydrogen, C1i 4 alkyl, CI- 3 alkoxyCI- 3 alkyl, aminoCI- 3 alkyl orhydroXYCI- 3 alkyl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof. WO 02/08213 PCT/GB01/02964 8. A compound according to claim 7 wherein: R' R 2 and R 3 are all Ci. 4 alkoxy; R 4 and R 6 are independently selected from hydrogen, hydroxy, Ci- 3 alkoxy, and Cl_ 3 alkyl; R 5 is methoxy; A is or -CONH-; a is 1,2 or 3; B is -NHCO-, -CONH, -NHC(O)O-, NHCONH- or a single direct bond; b is 0, 1 or 2; D is piperazinyl or morpholinyl or piperidinyl, each ring being optionally substituted by 1 or 2 substituents selected from Ci- 4 alkyl, C 2 4 alkanoyl, carbamoyl, cyanoC-1 3 alkyl, hydroxyCi_ 3 alkyl, carboxyCl_ 3 alkyl and aminoCl_3alkyl; R 7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof. 9. A compound according to claim 7 wherein: R R 2 and R 3 are all methoxy; R 4 and R 6 are independently selected from hydrogen, hydroxy, methoxy and methyl; R 5 is methoxy; A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is piperazino or morpholino, each ring being optionally substituted by 1 or 2 substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2- hydroxyethyl; R 7 is hydrogen; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof. WO 02/08213 PCT/GB01/02964 -51- A compound according to claim 7 wherein: MeO NH-A-(CH2)a-B-(CH2)b-D MeO OMe (IV) wherein a, b, A, B and D are as hereinabove defined in claim 7; or a pharmaceutically-acceptable salt, solvate or pro-drug thereof. 11. A compound according to claim 10 wherein: A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; bis 0or 1; D is piperazino or morpholino, each ring being optionally substituted by 1 or 2 substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2- hydroxyethyl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof. 12. A compound according to claim 10 wherein: A is or -CONH-; a is 2 or 3; B is -NHCO-, -CONH or a single direct bond; b is 0 or 1; D is morpholino, 4-methylpiperazin-l-yl or 4-acetylpiperazin-l-yl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof. 13. A compound selected from: -3,9,10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2- aminoacetylamino] acetamide; 4-oxo-4-[(5S)-3,9,10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5- yl]amino]butyl disodium phosphate; WO 02/08213 WO 0208213PCT/GB01/02964 52 N- N-[2-(irnidazol- 1 -yl)ethyllcarbamoyl 1-5 10,11 -tetramethoxy-6,7-dihydro-5H- and 2- {N-II(5S)-3,9, 10,1 1 -tetramethoxy-6,7-dihydro-5H-dibenzo yI] carbamnoyloxy 1 ethyl disodium phosphate; 2-morpholinoethyl N- 10,1 1-tetramethoxy-6,7-dihydro-5H-dibenzo 1 -methylpiperazin-4-yl)propyl N- 10,11 -tetramethoxy-6,7-dihydro-5H- dibenzo [a,clcyclohepten-5-yl] carbamnate; 10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2- [2- aminoacetylamino]acetamide; 1-acetylpiperazin-4-yl)ethyl-N-[(5S)-3 10,11 -tetramethoxy-6-7-dihydro-5H- carbamnate; 10,1 1-tetramethoxy-6-7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] 1- methylpiperazin-4-yl)-4-oxobutan-I-amide; 4-oxo-4- 10,11 -tetramethoxy-6,7-dihydro-5H-dibenzo[a,cjcyclohepten-5- yl]amnino]butyl disodium phosphate; N- [2-(imidazol-1I-yl)ethyl]carbamoyl)}-5(S)-3 10,11 -tetramethoxy-6,7-dihydro-5H- 3-(l1-acetylpiperazin-4-yl) propyl-N- [5S)-3,9,10,l1-tetramethoxy-6-7-dihydro-5H- N-i- [(5S 10,l1-tetramethoxy-6,7-dihydro-5H-dibenzo yl]carbamoyloxy]ethyl disodiumphosphate; 4-morpholino-4-oxobutyl-N-[(5S)-3,9, 10, 11 -tetramethoxy-6,7-dihydro-5H-dibenzo and 1-methylpiperazin-4-yl)-4-oxobutyl 10, 11 -tetramethoxy-6,7-dihydro- and pharmaceutically-acceptable salts, solvates or pro-drugs thereof. 14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, solvate or pro-drug thereof, in association with a pharmaceutically acceptable carrier. WO 02/08213 PCT/GB01/02964 -53- The use of a compound according any one claims 1 to 13, or a pharmaceutically- acceptable salt, solvate or pro-drug thereof, in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal. 16. The use of a compound according to any one of claim 1 to 13 or pharmaceutically- acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal. 17. A process for preparing a compound of the formula or a compound of the formula (I) wherein at least 1 functional group is protected, wherein R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 1 0 RR, R 12 R 13 R 14 A, B, D, a, b and c are as defined in claim 1, comprising: a) reacting a compound of the formula (X) 3 NH(R 7 R 4 RR R 1 S 5 (X) R 6 R R with a compound of the formula (XI): L' A [CH(Ra Rb )]b-D (XI) wherein L' is a leaving group; or b) converting one compound of the formula into another compound of the formula c) when a phosphoryloxy group is desired, reacting the corresponding hydroxy compound with a phosphoramidite; wherein any functional groups are optionally protected. and thereafter if necessary: i) converting a compound of formula into another compound of formula ii) removing any protecting groups; Pr.)PERMWUm\2s5IM16 dMc-w2M4 CS -54- Siii) forming a pharmaceutically acceptable salt, solvate or pro-drug thereof. 18. A method of producing a vascular damaging effect in a warm-blooded animal said method including the step of administering to said animal a pharmaceutically S 5 effective amount of a compound or a pharmaceutically acceptable salt, solvate or I\O pro-drug thereof according to any one of claims 1 to 13, or a pharmaceutical composition according to claim 14. O 19. A method according to claim 18 wherein the compound or a pharmaceutically acceptable salt, solvate or pro-drug thereof or composition is administered in divided doses. A compound of formula (III) or substantially as hereinbefore described with reference to the examples. DATED this 2 6 th day of August, 2005 Angiogene Pharmaceuticals Limited By DAVIES COLLISON CAVE Patent Attorneys for the Applicants
AU2001266232A 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors Ceased AU2001266232B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00401977 2000-07-07
EP00401977.4 2000-07-07
EP00401976 2000-07-07
EP00401976.6 2000-07-07
PCT/GB2001/002964 WO2002008213A1 (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
AU2001266232A1 AU2001266232A1 (en) 2002-05-02
AU2001266232B2 true AU2001266232B2 (en) 2005-09-15

Family

ID=26073520

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6623201A Pending AU6623201A (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors
AU2001266232A Ceased AU2001266232B2 (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU6623201A Pending AU6623201A (en) 2000-07-07 2001-07-04 Colchinol derivatives as angiogenesis inhibitors

Country Status (19)

Country Link
EP (1) EP1301498A1 (en)
JP (1) JP2004504391A (en)
KR (1) KR20030022264A (en)
CN (1) CN1255392C (en)
AU (2) AU6623201A (en)
BR (1) BR0112225A (en)
CA (1) CA2410562A1 (en)
CZ (1) CZ200331A3 (en)
EE (1) EE200300015A (en)
HU (1) HUP0301742A3 (en)
IL (1) IL153325A0 (en)
IS (1) IS6668A (en)
MX (1) MXPA02012903A (en)
NO (1) NO20030055L (en)
NZ (1) NZ522661A (en)
PL (1) PL359181A1 (en)
RU (1) RU2003103603A (en)
SK (1) SK52003A3 (en)
WO (1) WO2002008213A1 (en)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
SE9903544D0 (en) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0003828D0 (en) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
CN101607958A (en) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 Quinazoline compound
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
DE60318219T2 (en) 2002-08-24 2009-01-15 Astrazeneca Ab Pyrimidine derivatives as modulators of the activity of chemokine receptors
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DK1847539T3 (en) 2002-12-24 2009-11-09 Astrazeneca Ab Quinazoline derivatives
WO2004078126A2 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (en) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
EP1732920B1 (en) 2004-01-05 2011-03-09 AstraZeneca AB Thiophene derivatives as chk 1 inhibitors
SE0401657D0 (en) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
EP1809624B1 (en) 2004-08-28 2013-11-20 AstraZeneca AB Pyrimidine sulphonamide derivatives as chemokine receptor modulators
RS52036B (en) 2004-12-21 2012-04-30 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
ES2375735T3 (en) 2005-02-04 2012-03-05 Astrazeneca Ab USEFUL PIRAZOLILAMINOPIRIDINE DERIVATIVES AS QUINASE INHIBITORS.
CA2608201C (en) 2005-05-18 2013-12-31 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
JPWO2007034817A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
WO2007034916A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Novel adenine compound
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP1939199A4 (en) 2005-09-22 2010-10-20 Dainippon Sumitomo Pharma Co Novel adenine compound
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
EP1979001B1 (en) 2005-12-13 2012-04-11 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
ES2380683T3 (en) 2005-12-15 2012-05-17 Astrazeneca Ab Diphenyl ethers, amides, sulphides and substituted methanes for the treatment of respiratory disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2125722A2 (en) 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
DE102006037478A1 (en) 2006-08-10 2008-02-14 Merck Patent Gmbh 2- (Heterocyclylbenzyl) -pyridazinone derivatives
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
ES2385681T3 (en) 2006-12-19 2012-07-30 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
CL2008000191A1 (en) 2007-01-25 2008-08-22 Astrazeneca Ab COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER.
AR065784A1 (en) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.
JPWO2008114819A1 (en) 2007-03-20 2010-07-08 大日本住友製薬株式会社 New adenine compounds
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025718A1 (en) 2007-06-01 2008-12-04 Merck Patent Gmbh pyridazinone derivatives
DE102007025717A1 (en) 2007-06-01 2008-12-11 Merck Patent Gmbh Aryl ether pyridazinone derivatives
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
UA100983C2 (en) 2007-07-05 2013-02-25 Астразенека Аб Biphenyloxypropanoic acid as crth2 modulator and intermediates
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007038957A1 (en) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-thioxo-pyridazine derivatives
DE102007041115A1 (en) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
MX2010003698A (en) 2007-10-04 2010-04-21 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity.
RS53552B1 (en) 2007-10-11 2015-02-27 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
EP2245064B1 (en) 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
ES2394547T3 (en) 2008-02-06 2013-02-01 Astrazeneca Ab Compounds
WO2009108670A1 (en) 2008-02-28 2009-09-03 Merck Serono S.A. Protein kinase inhibitors and use thereof
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
BRPI0912103A2 (en) 2008-05-27 2021-04-20 Astrazeneca Ab phenoxypyridinylamide derivatives and their use in the treatment of pde4-mediated disease states
DE102008025750A1 (en) 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008029734A1 (en) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidine derivatives
TWI461423B (en) 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
DE102008037790A1 (en) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
DE102008052943A1 (en) 2008-10-23 2010-04-29 Merck Patent Gmbh azaindole derivatives
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
CN104860913B (en) 2008-12-11 2018-05-04 艾克赛特药品有限公司 The crystal form of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
AU2009333653B2 (en) 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
CA2745085C (en) 2008-12-18 2018-03-06 Merck Patent Gmbh Tricyclic azaindoles
DE102008063667A1 (en) 2008-12-18 2010-07-01 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
DE102008062825A1 (en) 2008-12-23 2010-06-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008062826A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh pyridazinone derivatives
DE102009003954A1 (en) 2009-01-07 2010-07-08 Merck Patent Gmbh pyridazinone derivatives
DE102009003975A1 (en) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102009004061A1 (en) 2009-01-08 2010-07-15 Merck Patent Gmbh pyridazinone derivatives
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
AU2010212590B2 (en) 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
UY32520A (en) 2009-04-03 2010-10-29 Astrazeneca Ab COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
DE102009043260A1 (en) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolone derivatives
MX2012003644A (en) 2009-10-02 2012-04-30 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase.
DE102009049679A1 (en) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
MX2012005329A (en) 2009-11-18 2012-05-29 Astrazeneca Ab Benzoimidazole compounds and uses thereof.
DK3279215T3 (en) 2009-11-24 2020-04-27 Medimmune Ltd TARGETED BINDING AGENTS B7-H1
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
DE102009058280A1 (en) 2009-12-14 2011-06-16 Merck Patent Gmbh thiazole
EP2513057B1 (en) 2009-12-14 2013-09-04 Merck Patent GmbH Sphingosine kinase inhibitors
JP2013514287A (en) 2009-12-17 2013-04-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhibitors of sphingosine kinase
ES2654584T3 (en) 2010-01-15 2018-02-14 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions and methods
AU2011208530A1 (en) 2010-01-19 2012-08-09 Astrazeneca Ab Pyrazine derivatives
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
US20130059916A1 (en) 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
DE102010034699A1 (en) 2010-08-18 2012-02-23 Merck Patent Gmbh pyrimidine derivatives
WO2012027957A1 (en) 2010-08-28 2012-03-08 Suzhou Neupharma Co., Ltd. Bufalin derivatives, pharmaceutical compositions and use thereof
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
DE102010048800A1 (en) 2010-10-20 2012-05-10 Merck Patent Gmbh quinoxaline
DE102010049595A1 (en) 2010-10-26 2012-04-26 Merck Patent Gmbh quinazoline derivatives
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
ES2575688T3 (en) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy
EP2651943B1 (en) 2010-12-17 2017-03-22 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives
CA2822515C (en) 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
EP2670763B1 (en) 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
MY180039A (en) 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
RS60190B1 (en) 2011-07-27 2020-06-30 Astrazeneca Ab 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
DE102011111400A1 (en) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclic heteroaromatic compounds
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9328081B2 (en) 2011-09-01 2016-05-03 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013040515A1 (en) 2011-09-14 2013-03-21 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013045955A1 (en) 2011-09-29 2013-04-04 The University Of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2012367141B2 (en) 2012-01-28 2016-12-22 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
WO2013117285A1 (en) 2012-02-09 2013-08-15 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
US9339503B2 (en) 2012-02-09 2016-05-17 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
WO2013126132A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
WO2013124026A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
JP6097770B2 (en) 2012-02-21 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Furopyridine derivatives
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
CN104169284B (en) 2012-03-28 2017-03-29 默克专利股份公司 Bicyclic pyrazinone derivatives
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
JP6007310B2 (en) 2012-04-05 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific antibodies against human TWEAK and human IL17 and uses thereof
EP3453713B1 (en) 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
ES2673873T3 (en) 2012-07-24 2018-06-26 Merck Patent Gmbh Hydroxystatin derivatives for the treatment of osteoarthritis
EP2882746B1 (en) 2012-08-07 2016-12-07 Merck Patent GmbH Pyridopyrimidine derivatives as protein kinase inhibitors
SG11201500732TA (en) 2012-08-08 2015-02-27 Merck Patent Gmbh (aza-)isoquinolinone derivatives
CN104736533B (en) 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3 inhibitor
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR102200628B1 (en) 2012-09-26 2021-01-08 메르크 파텐트 게엠베하 Quinazolinone derivatives as parp inhibitors
EP2911692B1 (en) 2012-10-26 2019-08-21 The University of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
CN104903467B (en) 2012-11-05 2020-09-08 Gmdx私人有限公司 Method for determining cause of somatic mutation
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
CA2891484A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP3381917B1 (en) 2013-01-31 2021-09-08 Bellus Health Cough Inc. Imidazopyridine compounds and uses thereof
JP6321685B2 (en) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 2-Amino-3,4-dihydro-quinazoline derivatives and their use as cathepsin D inhibitors
CN105026397B (en) 2013-03-05 2017-06-30 默克专利股份公司 As 9 (aryl or heteroaryl) 2 (pyrazolyl, pyrrolidinyl or cyclopenta) amino purine derivatives of anticancer
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer Hsp90-targeted cardiac imaging and therapy
US9937137B2 (en) 2013-03-15 2018-04-10 Neurocentria, Inc. Magnesium compositions and uses thereof for cancers
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
WO2014205511A1 (en) 2013-06-25 2014-12-31 University Of Canberra Methods and compositions for modulating cancer stem cells
RU2718876C2 (en) 2013-08-23 2020-04-15 Ньюфарма, Инк. Certain chemical compounds, compositions and methods
EP3046560B1 (en) 2013-09-18 2021-01-06 EpiAxis Therapeutics Pty Ltd Stem cell modulation ii
US20160298197A1 (en) 2013-10-01 2016-10-13 Queensland University Of Technology Kits and methods for diagnosis, screening, treatment and disease monitoring
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
WO2016029262A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
ES2883628T3 (en) 2014-11-17 2021-12-09 Univ Queensland Glycoprotein biomarkers for adenocarcinoma of the esophagus and Barrett's esophagus and their uses
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CA2976227C (en) 2015-02-17 2023-10-24 Neupharma, Inc. Quinazoline derivatives and their use in treatment of cancer
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
CN113336746A (en) 2015-08-04 2021-09-03 常州千红生化制药股份有限公司 N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds
JP6850294B2 (en) 2015-08-26 2021-03-31 ジーエムディーエックス カンパニー プロプライエタリー リミテッド How to Detect Cancer Recurrence
JP7412079B2 (en) 2015-12-23 2024-01-12 レプルカ プロプライアタリー リミティド Nucleic acid oligomers and their uses
CN108883155A (en) 2016-02-01 2018-11-23 堪培拉大学 Proteinate and application thereof
EP3417294B8 (en) 2016-02-15 2022-05-04 Astrazeneca AB Methods comprising fixed intermittent dosing of cediranib
US10844067B2 (en) 2016-04-15 2020-11-24 Cancer Research Technology Limited Heterocyclic compounds as RET kinase inhibitors
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
DK3490565T3 (en) 2016-07-29 2022-07-11 Rapt Therapeutics Inc AZETIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
EP4006035B1 (en) 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
US10919896B2 (en) 2016-09-22 2021-02-16 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
KR102495436B1 (en) 2016-12-05 2023-02-02 에이프로스 테라퓨틱스, 인크. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
SG11201907095UA (en) 2017-02-01 2019-08-27 Aucentra Therapeutics Pty Ltd DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
EP3592730B1 (en) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN108864079B (en) 2017-05-15 2021-04-09 深圳福沃药业有限公司 Triazine compound and pharmaceutically acceptable salt thereof
US11161839B2 (en) 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
IL270869B2 (en) 2017-05-26 2023-09-01 Cancer Research Tech Ltd Benzimidazolone derived inhibitors of bcl6
US11883405B2 (en) 2017-05-31 2024-01-30 Amplio Pharma Ab Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
EP3648797A1 (en) 2017-07-05 2020-05-13 EPOS-Iasis Research and Development, Ltd Multifunctional conjugates
ES2940407T3 (en) 2017-08-01 2023-05-08 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
EP3668882A1 (en) 2017-08-18 2020-06-24 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
JP7287952B2 (en) 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazole derivatives as adenosine receptor antagonists
DK3672951T3 (en) 2017-08-21 2023-11-20 Merck Patent Gmbh QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
TWI702205B (en) 2017-10-06 2020-08-21 俄羅斯聯邦商拜奧卡德聯合股份公司 Epidermal growth factor receptor inhibitors
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
BR112020009055A2 (en) 2017-11-06 2020-11-03 Rapt Therapeutics, Inc. chemokine receptor modulators for positive cancer treatment for epstein-Barr virus
ES2965337T3 (en) 2017-11-23 2024-04-12 Medac Ges Fuer Klinische Spezialpraeparate Mbh Pharmaceutical composition for oral administration containing sulfasalazine and/or an organic salt of sulfasalazine, production process and use
EP3489222A1 (en) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazine salts, production processes and uses
EP3740484B1 (en) 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
IL276295B2 (en) 2018-01-26 2024-02-01 Rapt Therapeutics Inc Chemokine receptor modulators and uses thereof
WO2019157225A2 (en) 2018-02-08 2019-08-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
MX2020010805A (en) 2018-04-13 2021-01-29 Cancer Research Tech Ltd Bcl6 inhibitors.
CN112423747A (en) 2018-04-27 2021-02-26 云杉生物科学公司 Methods for treating testicular and ovarian adrenal residual tumors
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
JP7351859B2 (en) 2018-06-04 2023-09-27 アプロス セラピューティクス， インコーポレイテッド Pyrimidine compounds containing acidic groups useful for treating diseases related to TLR7 regulation
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
ES2971927T3 (en) 2018-09-18 2024-06-10 Hoffmann La Roche Quinazoline derivatives as antitumor agents
WO2020068600A1 (en) 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
US20210361669A1 (en) 2018-10-25 2021-11-25 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
BR112021007435A2 (en) 2018-10-25 2021-08-03 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
WO2020132844A1 (en) 2018-12-25 2020-07-02 中国医学科学院基础医学研究所 Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
AR117844A1 (en) 2019-01-22 2021-09-01 Merck Patent Gmbh THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR
JP2022524759A (en) 2019-03-07 2022-05-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Carboxamide-pyrimidine derivative as an SHP2 antagonist
CN111747950B (en) 2019-03-29 2024-01-23 深圳福沃药业有限公司 Pyrimidine derivatives for the treatment of cancer
US20230085408A1 (en) 2019-04-05 2023-03-16 STORM Therapeutics Ltd. Mettl3 inhibitory compounds
CA3127475A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
US20220298143A1 (en) 2019-08-31 2022-09-22 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
TW202120501A (en) 2019-09-20 2021-06-01 美商愛德亞生物科學公司 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
KR20220113431A (en) 2019-12-02 2022-08-12 스톰 테라퓨틱스 리미티드 Polyheterocyclic Compounds as METTL3 Inhibitors
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
IL308163A (en) 2021-05-03 2024-01-01 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
AU2022276958A1 (en) 2021-05-17 2023-12-07 Hk Inno.N Corporation Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
IL308818A (en) 2021-05-25 2024-01-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023057389A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag Parg inhibitory compounds
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
AU2023205435A1 (en) 2022-01-10 2024-08-22 Cancer Research Horizons Substituted heterocycles as hset inhibitors
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
WO2023218201A1 (en) 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2024094962A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
WO2024094963A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
WO2024099898A1 (en) 2022-11-07 2024-05-16 Merck Patent Gmbh Substituted bi-and tricyclic hset inhibitors
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
US20240327430A1 (en) 2023-03-10 2024-10-03 Breakpoint Therapeutics Gmbh Novel compounds, compositions, and therapeutic uses thereof
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents

Also Published As

Publication number Publication date
HUP0301742A2 (en) 2003-09-29
JP2004504391A (en) 2004-02-12
IL153325A0 (en) 2003-07-06
EP1301498A1 (en) 2003-04-16
HUP0301742A3 (en) 2005-08-29
EE200300015A (en) 2004-10-15
AU6623201A (en) 2002-02-05
CZ200331A3 (en) 2003-04-16
BR0112225A (en) 2003-05-06
NZ522661A (en) 2004-07-30
CA2410562A1 (en) 2002-01-31
CN1255392C (en) 2006-05-10
CN1440396A (en) 2003-09-03
MXPA02012903A (en) 2004-07-30
SK52003A3 (en) 2003-07-01
NO20030055D0 (en) 2003-01-06
WO2002008213A1 (en) 2002-01-31
IS6668A (en) 2003-01-03
NO20030055L (en) 2003-01-06
KR20030022264A (en) 2003-03-15
PL359181A1 (en) 2004-08-23
RU2003103603A (en) 2004-08-20

Similar Documents

Publication Publication Date Title
AU2001266232B2 (en) Colchinol derivatives as angiogenesis inhibitors
AU2001266233B2 (en) Colchinol derivatives as vascular damaging agents
AU2001266232A1 (en) Colchinol derivatives as angiogenesis inhibitors
AU2001266233A1 (en) Colchinol derivatives as vascular damaging agents
EP1140745B1 (en) Colchinol derivatives as vascular damaging agents
WO1994018987A1 (en) Drug composition containing nucleic acid copolymer
ZA200004386B (en) Anti-tumour agents.
US6720323B2 (en) Colchinol derivatives as angiogenesis inhibitors
CA3108638A1 (en) Conjugates for use in methods of treating cancer
US6136857A (en) Methods for treating neoplasms with betaines
US6346633B1 (en) Anti-tumuor agents
CH657608A5 (en) THIOCARNITINE AND PROCEDURE FOR THEIR PREPARATION.
ZA200207108B (en) Divided dose therapies with vascular damaging activity.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired